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1 Introduction 
1.1 Parkinson’s disease 
Parkinson’s disease (PD) is the most common movement disorder and the second most 
frequent neurodegenerative disease after Alzheimer’s disease (AD). With increased life 
expectancy and an aging society, the incidence of PD is expected to dramatically increase 
within the next decades. Current therapy is mainly based on a dopamine replacement 
strategy, commonly using the dopamine precursor levodopa. However, long-term treatment 
is associated with motor complications, and to date there is no cure for the disease. It is thus 
important to search for new therapeutic options and identify novel targets for disease 
modification to help PD patients improve their daily lives. In order to achieve this it is 
necessary to provide a better understanding of the molecular pathomechanisms underlying 
the disease. 
1.1.1 Etiology 
PD is a complex disease with contribution of both environmental and genetic factors. 
Although most cases are sporadic with no family history, monogenetically inherited forms of 
PD are present in some families. In addition, large genome-wide association studies (GWAS) 
have identified several genetic risk factors. Aging is the major risk factor for sporadic PD. 
Normal aging is associated with a loss of about 1 % of total neurons in the substantia nigra 
pars compacta (SNc) per decade, while during PD pathogenesis neuronal cell death is 
accelerated to approximately 10 % loss of neurons within ten years.  
Besides aging, environmental factors are considered important for the development of the 
disease. First evidence was presented in 1983, when Langston and coworkers reported a 
series of young drug addicts developing PD upon accidental exposure to MPTP, a toxic 
byproduct of the clandestine synthesis of a pethidine analogue (Langston et al., 1983). 
Furthermore, pesticides such as paraquat or rotenone and heavy metal exposure, in 
particular manganese, have been identified as environmental risk factors that contribute to 
the disease. Conversely, some factors seem to decrease the risk for PD. Epidemiological 
studies have linked cigarette smoking, caffeine intake and potentially the use of 
anti-inflammatory drugs to a significantly decreased risk to develop PD (Powers et al., 2008). 
Although most PD cases are sporadic with no obvious family history, about 10-20 % of 
patients display a genetic inheritance pattern with at least one affected first degree relative. 
To date, mutations in six genes have been unequivocally connected to familiar forms of the 
disease. In addition, genetic risk factors associated with PD have been found in large GWAS. 
The genetic contribution to PD will be discussed in section 1.3. 
In conclusion, genetic predisposition and environmental factors seem to contribute to PD 
pathogenesis (see Figure 1). 
Introduction 
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Figure 1: Etiology of PD. Most PD cases are sporadic with no obvious family history. Familiar forms of the 
disease are caused by genetic mutations with either autosomal dominant or recessive inheritance pattern. 
Several genetic risk factors are associated with PD. Environmental factors such as the exposure to toxins are also 
connected to an increased risk of PD development. Adopted from (Pilsl and Winklhofer, 2011).
1.1.2 Pathology 
PD is characterized by a degeneration of neurons in the substantia nigra pars compacta 
(SNc) and the occurrence of Lewy Bodies (LB) and Lewy Neurites (LN). However, pathology 
is not restricted to the SNc, but involves areas such as cortex, amygdala, locus coeruleus, 
the nucleus basalis of Meynert, and the peripheral autonomic nervous system. LBs are 
proteinaceous cytoplasmic inclusions containing -synuclein, chaperones, ubiquitin, 
neurofilament, and several other proteins. They are about 10 μM in diameter with a dense 
core and a clear halo (Figure 2). 
Surprisingly, first PD symptoms occur when about 80 % of dopaminergic neurons in the SNc 
have perished. It is largely unclear what causes the neuronal cell death and why 
dopaminergic neurons in the SNc are particularly susceptible to demise. Scenarios 
explaining possible mechanisms of neurodegeneration involve mitochondrial dysfunction, 
oxidative stress, excitotoxicity, apoptosis and inflammation, and 
ubiquitin-proteasomal-system (UPS) dysfunction accompanied by deposition of abnormal 
protein species.  
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Figure 2: Morphological appearance of Lewy bodies. Left: Hematoxylin and eosin staining of a midbrain 
section from a PD patient. The intracellular Lewy body displays a typical dense core and a clear halo. The dark 
granules contain neuromelanin, a typical component of dopaminergic neurons in the SNc 
(source:http://neuropathology web.org/chapter9/images9). Right: Lewy body in a dopaminergic neuron of a PD 
patient stained for -synuclein (yellow) and ubiquitin (red). Source: (Olanow et al., 2009).  
1.1.3 Symptoms and Diagnosis 
The cardinal symptoms of PD are motor symptoms: resting tremor, rigidity, bradykinesia, and 
postural instability. Besides these motor complications a variety of other symptoms can occur 
such as autonomic dysfunction (blood pressure and temperature dysregulation, sensory 
deficits, sleep disturbances) and neuropsychiatric complaints (depression, cognitive 
impairment, dementia) in a large subset of patients.  
Onset of symptoms is typically between the 5th and 6th decade of life, although some 
monogenic forms of the disease display an earlier manifestation. To date, clinical diagnosis 
is largely based on exclusion with a positive response to levodopa as a major criterion. A 
definite diagnosis of PD can only be made upon post mortem autopsy. 
1.1.4 Current treatment options 
Current PD therapy is mainly based on dopamine replacement strategies with levodopa as 
the gold standard. Levodopa is usually administered in combination with peripheral 
decarboxylase inhibitors to increase drug availability in the central nervous system. 
Monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT) inhibitors slow down 
the metabolism of dopamine. An additional focus of therapeutic intervention is the treatment 
of non-motor symptoms. Several ongoing studies investigate the effect of neuroprotectants 
on disease progression, such as co-enzyme Q10 and vitamine E (reviewed in (Olanow et al., 
2009)). 
Unfortunately, most patients develop dyskinesias following several years of treatment. These 
involuntary movements are difficult to control and significantly impair the quality of life. 
Surgical approaches such as deep brain stimulation is used in patients where medical 
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interventions fail. Furthermore, intensive research efforts are undertaken using 
transplantation approaches including induced pluripotent stem cells, embryonic stem cells 
and tissue grafts (reviewed in (Dyson and Barker, 2011)). 
1.2 PD and mitochondria 
1.2.1 Importance of mitochondria for cellular homeostasis 
Mitochondria – the “cellular powerhouses” – are found in almost all eukaryotic cells. They 
serve a wide spectrum of important functions; most notably they are involved in energy 
production in form of ATP. Furthermore, mitochondria are part of other metabolic pathways 
such as -oxidation of fatty acids. Mitochondria control calcium homeostasis and apoptosis 
induction. Proper mitochondrial function is essential for cellular homeostasis, especially in 
cells with high energy demand such as liver, muscle, and neuronal cells. Thus, different 
mitochondrial quality control mechanisms are employed at different levels: mitochondrial 
biogenesis, the synthesis of new mitochondria, control of mitochondrial morphology via 
modulation of mitochondrial dynamics, and degradation of defective mitochondria through 
mitophagy.  
In the first place, mitochondrial biogenesis is adjusted to cellular needs. Synthesis of 
additional mitochondria is triggered by a variety of different environmental stimuli or during 
cellular stress conditions including temperature, energy deprivation, and availability of 
nutrients and growth factors. Mitochondrial biogenesis is controlled by the interplay of 
nuclear and mitochondrial factors. The majority of mitochondrial proteins are transcribed from 
the nuclear genome, while the circular mitochondrial genome encodes parts of the electron 
transport chain and mitochondrial RNAs. The main regulator of mitochondrial biogenesis 
appears to be the peroxisome proliferator-activated receptor gamma 1 alpha (PGC-1), 
which activates the mitochondrial transcription factor A (TFAM) and nuclear respiratory 
factors 1 and 2 (NRF1/2). As transcription factors, NRFs are directly involved in the 
transcription of nuclear-encoded mitochondrial genes while TFAM is a major regulator of 
mitochondrial gene transcription. 
Mitochondrial quality is also ensured and controlled through changes in mitochondrial 
dynamics. The mitochondrial fusion and fission machinery is highly conserved in eukaryotic 
cells. In mammals, mitochondrial fusion is regulated by at least three membrane-bound 
GTPases: the mitofusins 1 and 2 (Mfn1/2) regulate fusion of the outer mitochondrial 
membrane (OMM), while optic atrophy 1 (Opa1) mediates inner mitochondrial membrane 
(IMM) fusion. Mitochondrial fission is accomplished by translocation of the cytosolic 
dynamin-related protein 1 (Drp1) to future scission sites at mitochondria (Figure 3). 
Mitochondria are quite dynamic organelles that constantly fuse and divide. Disturbances in 
mitochondrial dynamics can be devastating, in particular for neurons. As a matter of fact, 
mutations in key genes regulating mitochondrial dynamics can result in neurodegenerative 
diseases in humans: Opa1 was determined to be mutated in dominant optic atrophy, the 
most frequent hereditary optic neuropathy (Alexander et al., 2000, Delettre et al., 2000). 
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Charcot-Marie-Tooth disease type 2A, a peripheral demyelinating neuropathy, is caused by 
mutations in the MFN2 gene (Zuchner et al., 2004). In agreement with a protective function 
of mitochondrial dynamics, a decline in respiratory activities has been observed in 
fusion-deficient fibroblasts from mice lacking Opa1 or mitofusins (Chen et al., 2005, Chen et 
al., 2007). 
Interestingly, it has been demonstrated that dysfunctional mitochondria can be recovered by 
means of mitochondrial dynamics: single mitochondria with mutations in mitochondrial DNA 
(mtDNA) are able to fuse with the mitochondrial network to obtain intact mtDNA from 
neighboring mitochondria (Twig et al., 2008a, Twig et al., 2008b), preventing the 
accumulation of mtDNA mutations. A balance in mitochondrial dynamics is particularly 
important for neurons (reviewed in (Pilsl and Winklhofer, 2011)): 1) Mitochondria require 
long-distance transport along microtubules from the location of synthesis in the soma to sites 
of high energy demand such as the synapse. 2) Neurons are postmitotic cells, thus an 
efficient quality control is crucial for cell survival and 3) Nerve cells are characterized by high 
rates of metabolic activity, thus they require effective supply of energy provided by the 
mitochondrial respiratory chain (reviewed in (Gusdon and Chu, 2011)).  
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Figure 3: Mitochondrial dynamics. Mitochondrial morphology is controlled by mitochondrial fusion and fission 
processes. Mitochondrial outer membrane fusion is mediated by mitofusins 1 and 2, while inner membrane fusion 
is controlled by Opa1. During fission of mitochondria, Drp1 translocates from the cytosol to scission sites where it 
multimerizes and forms ring-shaped structures constricting mitochondria. 
 
In addition, the degradation of dysfunctional or superfluous mitochondria is an essential part 
of mitochondrial quality control. Mitochondria are the major source of reactive oxygen 
species (ROS) which can be detrimental to cells. Furthermore, the intrinsic pathway of 
apoptosis can be induced by the release of cytochrome c from mitochondria. Removal of 
mitochondria is achieved via autophagic degradation of the organelles, a process termed 
mitophagy (discussed in detail in section 1.5.2). Mitophagy can be induced under different 
cellular conditions: analogous to non-selective, bulk-degradation macroautophagy, 
mitophagy can be triggered by starvation (reviewed in (Inoue and Klionsky, 2010)). In 
contrast, selective removal of mitochondria is induced in the course of erythrocyte 
maturation, and to prevent damage to cells when mitochondria are senescent or defective 
(see also section 1.5.2 and (Mortensen et al., 2010a, Mortensen et al., 2010b)). 
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Due to the important role of mitochondria for the cell, a tight regulation of mitochondrial 
biogenesis, dynamics and degradation is essential and the different quality mechanisms 
have to be balanced well in order to keep cellular homeostasis (Figure 4). 
1.2.2 PD and mitochondrial dysfunction 
As a consequence of the past decades of PD research it becomes increasingly evident that 
mitochondrial dysfunction plays a major role in disease pathogenesis. A first connection 
between PD and mitochondrial dysfunction emerged from the accidental exposure of drug 
addicts to the meperidine analogue 1-methyl-4-phenyl-1,2,3,6-tetrahydrodropyridine (MPTP) 
which induces a parkinsonian syndrome (Langston et al., 1983). MPTP is converted to the 
metabolite 1-methyl-4-phenylpyridinium (MPP+) in glia cells and selectively taken up by 
dopaminergic neurons via the dopamine transporter where it inhibits complex I of the 
mitochondrial respiratory chain, ultimately resulting in the degeneration of dopaminergic 
neurons. In agreement with these observations, a complex I deficit has been identified in 
post mortem brain samples in the SNc of PD patients (Parker et al., 2008, Janetzky et al., 
1994, Mizuno et al., 1989). Moreover, complex I deficiency is not restricted to SNc, but can 
be found in a variety of different tissues, including platelets, skeletal muscle and glia cells, 
although this is not a consistent observation among different studies (reviewed in 
(Reichmann and Janetzky, 2000)).  
In brains of PD patients, an increase in reactive oxygen species (ROS) has been observed. 
ROS is mainly produced by mitochondrial defects or leakage of protons in the mitochondrial 
respiratory chain. This results in a decrease in oxidative phosphorylation and an increase in 
the generation of reactive oxygen and nitrogen species (ROS and RNS). The substantia 
nigra is a site of free radical damage to mtDNA, and this damage is enhanced in PD patients 
(reviewed in (Schapira, 2008)). Not only MPP+ but also other environmental toxins interfering 
with mitochondrial function are implicated in PD pathogenesis. Rotenone, a broad-spectrum 
insecticide and piscicide, acts by inhibiting complex I of the electron transport chain. Similar 
to MPP+, rotenone is used in rodents and primates to induce a parkinsonian phenotype and 
model PD in animals (reviewed in (Bove et al., 2005)). The herbicide paraquat catalyzes the 
formation of superoxide free radicals, a major source of ROS, and triggers degeneration of 
dopaminergic neurons. The exposure of humans to paraquat or rotenone is associated with 
increased incidence of PD in case-control studies (reviewed in (Tanner et al., 2011)).  
Besides environmental factors genetic predisposition can affect mitochondrial function and 
subsequent PD pathogenesis. As an example, mutations in the mitochondrial polymerase 
POLG1 cause ophtalmoplegia and parkinsonism (Hudson et al., 2007). The interest in 
mitochondrial alterations linked to PD tremendously increased when it became evident that 
some PD-associated genes have a direct or indirect impact on mitochondrial integrity. A 
subset of gene products connected to familial forms of PD localize to mitochondria or 
influence aspects of mitochondrial quality control. The influence of PD-associated genes on 
mitochondria will be discussed in detail in the following sections (see section 1.3).
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Figure 4: Mitochondrial quality control mechanisms. Both intrinsic and extrinsic factors can influence 
mitochondrial homeostasis. This can manifest in different ways such as altered mitochondrial biogenesis and 
repair, bioenergetics and/or dynamics. 
1.3 Genetics of PD 
Many lines of evidence indicate that sporadic or idiopathic PD is caused by the interplay of 
environmental factors and genetic predisposition. Genetic studies have provided valuable 
insights into the pathological mechanisms underlying PD. In fact, roughly 10 % of PD cases 
are monogenetically inherited. 
Our understanding of the cellular mechanisms underlying PD pathogenesis emerged from 
the identification of mutations in the gene encoding -synuclein and the demonstration that 
-synuclein is the major constituent of Lewy bodies (Polymeropoulos et al., 1997, Spillantini 
et al., 1997). Although the exact cellular function of -synuclein has not been elucidated, the 
protein has been implicated in binding to lipid membranes and possibly acting as a molecular 
chaperone in the formation of SNARE complexes (Kamp et al., 2010, Chandra et al., 2005, 
Burre et al., 2010). 
Thereafter, mutations in other genes have been assigned to familial PD. Meanwhile, at least 
16 loci (designated as PARK1 to PARK16, see table 1) have been associated with inherited 
forms of PD, six of which have been unequivocally linked to PD pathogenesis. Mutations in 
-synuclein and leucine-rich repeat kinase 2 (LRRK2) display an autosomal-dominant 
inheritance pattern. Of note, recent GWAS have implicated genetic variability at these two 
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loci, -synuclein and LRRK2, as significant risk factors for developing sporadic PD 
(Consortium" et al., 2011, Pankratz et al., 2009, Pankratz et al., 2012, Lill et al., 2012). 
Contrarily, mutations in parkin, PINK1 (PTEN-induced kinase 1), DJ-1 and ATP13A2 are 
autosomal-recessively inherited. Interestingly, the symptoms of patients with mutations in PD 
genes are clinically indistinguishable from those suffering from sporadic PD, suggesting 
possible common pathomechanisms. Moreover, there is mounting evidence that parkin and 
PINK1 function in a mutual cellular pathway, and this will be discussed in detail in the 
following sections (see sections 1.4 and 1.5). 
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Table 1: Summary of genes and loci associated with PD. 
Genetic locus Gene product Inheritance Gene function 
   
 
PARK1/4 -synuclein AD, RF vesicle dynamics, lipid binding, 
synaptic transmission 
 
PARK2 parkin AR E3 ubiquitin ligase  
PARK3 unknown AD unknown  
PARK5 UCH-L1 AD enzyme involved in ubiquitination and 
deubiquitination 
 
PARK6 PINK1 AR mitochondrial kinase  
PARK7 DJ-1 AR redox-sensitive protein  
PARK8 LRKK2 AD, RF serine/threonine kinase, GTPase  
PARK9 ATP13A2 AR lysosomal ATPase  
PARK10 unknown RF unknown  
PARK11 GIGYF2 AD possibly involved in tyrosine kinase 
receptor signaling 
 
PARK12 unknown RF unknown  
PARK13 HtrA2/OMI AD mitochondrial serine protease  
PARK14 PLA2G6 AR lipid metabolism  
PARK15 FBXO7 AR SFC ubiquitin ligase  
PARK16 unknown RF unknown  
Not assigned GBA GD lysosomal enzyme  
Abbreviations:  
AD: autosomal dominant; AR: autosomal recessive; RF: risk factor for sporadic PD; GD: Gaucher’s Disease 
FBXO7: F-box only protein 7; GBA: glucocerobrosidase A; GIGYF2: GRB10 interacting GYF protein 2; 
HtrA2/OMI: high temperature requirement protein A2; LRRK2: leucine-rich repeat kinase 2; PINK1: 
PTEN-induced kinase 1; PLA2G6: phospholipase A2, group VI; SFC: Skp1-Cullin-F-box protein; 
UCH-L1: ubiquitin carboxyl-terminal esterase L1 
    
1.4 PINK1 
PINK1 (PTEN-induced kinase 1) is a ubiquitously expressed mitochondrial serine-threonine 
kinase comprising 581 amino acids. It contains an N-terminal mitochondrial targeting signal 
(MTS), a transmembrane sequence (TM) and a C-terminal kinase domain (Figure 5). 
Mutations in PINK1 have been connected to autosomal-recessive parkinsonism (Valente et 
al., 2004). Approximately 50 different mutations in PINK1 have been associated with the 
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disease, including missense and truncation mutations as well as large genomic 
rearrangements and deletions (see the Parkinson Disease Mutation Database PDmutDB 
found at http://www.molgen.ua.ac.be/PDmutDB; also reviewed in (Nuytemans et al., 2010)). 
Furthermore, heterozygous PINK1 mutations might be a risk factor for sporadic PD (Abou-
Sleiman et al., 2006). Similarly to parkin, the PINK1 protein is highly conserved among 
multicellular species. Valuable insights into the function of PINK1 resulted from the analysis 
of animal models. Drosophila PINK1 mutants display reduced life span, male sterility and 
apoptotic flight muscle degeneration (Clark et al., 2006, Park et al., 2006, Yang et al., 
2006a). In contrast, ablation of PINK1 in mice does not result in an overt phenotype. Aged 
PINK1 knockout mice display only minor deficits such as a mild decrease in total dopamine 
levels and an impaired synaptic plasticity in the striatum (Gispert et al., 2009, Kitada et al., 
2007) and minor gait alterations and olfactory dysfunctions (Glasl et al., 2012). However, no 
dopaminergic cell death has been observed in the substantia nigra or the striatum of mice 
lacking PINK1 (Kitada et al., 2009, Kitada et al., 2007, Gispert et al., 2009, Zhou et al., 
2007). 
 
 
 
Figure 5: Modular structure of PINK1. The PINK1 protein contains an N-terminal mitochondrial targeting 
sequence (MTS), a transmembrane domain (TM) and a C-terminal kinase domain. Numbers below indicate the 
domain borders (amino acid positions). 
The subcellular localization of PINK1 is still under extensive debate. Although PINK1 
contains a mitochondrial targeting signal and a transmembrane sequence (Silvestri et al., 
2005), several groups have identified a proportion of the protein in the cytosol (Weihofen et 
al., 2008, Takatori et al., 2008, Beilina et al., 2005, Haque et al., 2008, Lin and Kang, 2008, 
Lin and Kang, 2010). A recent report presents evidence that the PINK1 protein resides in the 
outer mitochondrial membrane with its kinase domain facing the cytoplasm (Zhou et al., 
2008). Interestingly, cytosolic PINK1 lacking the mitochondrial import sequence and the 
transmembrane domain displays neuroprotective activity in vivo, suggesting that cytosolic 
PINK1 may have a function in neuronal survival (Haque et al., 2008). Analysis of PINK1 
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subcellular localization is difficult owed to the lack of an appropriate antibody detecting 
endogenous PINK1. Notably, PINK1 levels are low under basal conditions. Recent evidence 
indicates that PINK1 protein is kept at low levels through instant shedding of the protein 
during or shortly after mitochondrial import, most likely via cleavage mediated by the 
protease presenilin-associated rhomboid-like (PARL) or its homologue rhomboid-7 in 
Drosophila  (Deas et al., 2011, Jin et al., 2010, Meissner et al., 2011, Shi et al., 2011, 
Whitworth et al., 2008). However, when the mitochondrial membrane potential is lost, PINK1 
processing is inhibited and full-length PINK1 is stabilized at the OMM (Narendra et al., 
2010b, Beilina et al., 2005, Lin and Kang, 2010, Jin et al., 2010, Deas et al., 2011). 
Interestingly, stablization of PINK1 at mitochondria seems crucial for the recruitment of 
parkin to mitochondria during mitophagy (see section 1.5.2). 
Different substrates have been suggested to be phosphorylated by PINK1. The first identified 
substrate of PINK1 is TNF-receptor associated receptor 1 (TRAP1), a mitochondrial 
chaperone (Pridgeon et al., 2007). Phosphorylation of TRAP1 by PINK1 is able to confer the 
protective activity of PINK1 against oxidative stress by inhibiting the release of cytochrome c 
from mitochondria. Another PINK1 substrate identified is high temperature regulation A2 
(HtrA2/OMI). Upon stimulation of the p38 stress kinase pathway, HtrA2/OMI is 
phosphorylated at a conserved serine residue in a PINK1-dependent manner (Plun-Favreau 
et al., 2007). Recently, PINK1 has also been found in a multiprotein complex together with 
Miro and Milton (Weihofen et al., 2009). The atypical GTPase Miro and the adaptor protein 
Milton are two proteins at the outer mitochondrial membrane that link kinesin heavy chains to 
mitochondria for anterograde axonal transport along microtubules. In accordance with this 
are recently published observations that PINK1 regulates Miro, possibly via phosphorylation, 
resulting in decreased levels of Miro and inhibiting axonal mitochondrial transport (Liu et al., 
2012, Wang et al., 2011). An interaction of PINK1 and parkin has been observed in some 
studies, and possibly PINK1 might directly phosphorylate parkin under certain conditions 
(Kim et al., 2008, Shiba et al., 2009, Um et al., 2009). Notably, an epistatic interaction of 
parkin and PINK1 has been observed in Drosophila, where parkin is sufficient to rescue the 
PINK1 loss-of-function phenotype (see references (Clark et al., 2006, Park et al., 2006, Yang 
et al., 2006a) and section 1.6). 
Similarly to parkin, the PINK1 protein has been implicated in cellular stress resistance (see 
section 1.5.1). Overexpression of PINK1 protects cells from cell death induced by 
staurosporine, a general kinase inhibitor (Petit et al., 2005). As mentioned before, the 
stress-protective effect of PINK1 can be mediated by direct phosphorylation of its substrate 
TRAP1, and mutations in the kinase domain of PINK1 abolish its cytoprotective activity 
(Pridgeon et al., 2007). In contrast, downregulation of PINK1 enhances apoptosis in the 
neuroblastoma cell line SH-SY5Y under cellular stress conditions (Deng et al., 2005). In line 
with this, Drosophila mutants lacking PINK1 exhibit widespread apoptosis, most prominently 
in indirect flight muscles. In the worm Caenorhabditis elegans loss of Pink-1 leads to an 
increased sensitivity to paraquat treatment (Samann et al., 2009). Accordingly, skin 
fibroblasts from PD patients harboring PINK1 mutations display increased vulnerability to 
proteasomal stress (Klinkenberg et al., 2010). Hence, PINK1 might be essential for 
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maintaining neuronal homeostasis, thus preventing neuronal degeneration. However, it 
remains to be determined if the protective activity of PINK1 depends on parkin and vice 
versa. 
1.5 Parkin 
Mutations in the parkin gene (PARK2 locus) are responsible for the majority of autosomal 
recessive PD cases. More than one hundred pathogenic parkin mutations have been 
identified, ranging from missense and nonsense mutations to large genomic deletions (see 
the Parkinson Disease Mutation Database PDmutDB http://www.molgen.ua.ac.be/PDmutDB; 
also reviewed in (Nuytemans et al., 2010)). The parkin gene comprises 12 exons, encoding 
for the 465 amino acid cytosolic parkin protein. The parkin protein contains an N-terminal 
ubiquitin-like domain (UBL), an atypical RING 0 domain involved in zinc binding and a 
C-terminal RING-between-RING (RBR) domain (Figure 6). Similarly to other RING finger 
proteins, parkin functions as an E3 ubiquitin ligase, mediating substrate specificity for the 
ubiquitination of substrate proteins. During the past decade a plethora of parkin substrates 
have been proposed, including parkin-associated endothelin receptor-like receptor (Pael-R), 
synphilin-1, glycosylated -synuclein, cyclin E, synaptotagmin XI, CASK, the p38/JTV-1 
subunit of the multi-tRNA synthetase complex, the PD-associated PINK1 protein and the 
parkin-interacting substrate (PARIS) (Zhang et al., 2000, Chung et al., 2001, Imai et al., 
2001, Shimura et al., 2001, Choi et al., 2003, Corti et al., 2003, Huynh et al., 2003, Ren et 
al., 2003, Staropoli et al., 2003, Fallon et al., 2006a, Shin et al., 2011). Although initial 
studies pointed towards a role of parkin in proteasomal degradation by the attachment of 
lysine-48 (K48) linked polyubiquitin chains, there is in vitro evidence that it can also mediate 
the addition of lysine-63 polyubiquitin (K63) chains (Sha et al., 2010, Olzmann et al., 2007, 
Lim et al., 2005, Henn et al., 2007) or monoubiquitin (Fallon et al., 2006b, Hampe et al., 
2006, Joch et al., 2007, Liu et al., 2008, Matsuda et al., 2006, Moore et al., 2008, Trempe et 
al., 2009). 
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Figure 6: Modular structure of parkin. The parkin protein contains an N-terminal ubiquitin-like domain (UBL) 
and a C-terminal RBR (RING-between RING) domain. The RBR domain consists of two RING domains and an 
in-between RING domain (IBR) and mediates the E3 ubiquitin ligase activity of parkin. An additional atypical 
RING domain has been identified (RING 0). Amino acid positions of the individual domains are given below. 
 
Insights into the in vivo function of parkin originated from the analysis of different animal 
models. Drosophila parkin null mutants display a strongly reduced lifespan, male sterility and 
locomotion abnormalities. Apoptotic flight muscle degeneration is observed, most likely 
resulting from mitochondrial alterations and functional deficits. In contrast to PD patients, no 
degeneration of dopaminergic neurons is detected in parkin-deficient flies (Clark et al., 2006, 
Greene et al., 2003, Park et al., 2006, Yang et al., 2006a). Overexpression of wildtype parkin 
in flies does not result in phenotypical alterations, by contrast, overexpression of the 
pathogenic parkin mutants Q311X or R275W causes neuronal and muscular degeneration, 
implying a possible toxic gain-of-function mechanism of pathogenic parkin mutants (Sang et 
al., 2007, Wang et al., 2007). In contrast to the severe phenotype observed in Drosophila, 
targeted deletion of parkin in rodents does not result in a severe phenotype. Parkin-deficient 
mice exhibit only minor changes in dopamine release and deficits in spatial learning while 
motor skills are not impaired (Goldberg et al., 2003, Von Coelln et al., 2004, Sato et al., 
2006, Zhu et al., 2007b). 
Many different functions have been attributed to parkin, the most consistent and favored 
being parkin-dependent cytoprotection and parkin-mediated mitophagy that are presented in 
the following chapters.  
 
1.5.1 Parkin protects cells against a broad range of toxic insults 
Parkin is a stress-responsive and stress-protective protein. It is upregulated upon various 
stress paradigms (Fett et al., 2010, Bouman et al., 2011, Imai et al., 2000, Yang et al., 
2006b). Accordingly, parkin confers protectivity against different cellular stressors, thus 
preventing apoptotic cell death. Parkin is able to protect cells in vitro and in animal models 
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from toxicity induced by dopamine (Hasegawa et al., 2008), ceramide (Darios et al., 2003), 
kainate (Henn et al., 2007), rotenone (Henn et al., 2007) and various other stress conditions 
(Petrucelli et al., 2002, Staropoli et al., 2003, Higashi et al., 2004, Jiang et al., 2004). In 
contrast, downregulation of parkin enhances stress-induced cell death (MacCormac et al., 
2004, Yang et al., 2007, Henn et al., 2007). In line with this, Drosophila parkin null mutants 
exhibit enhanced sensitivity to oxidative stress (Pesah et al., 2004). Additionally, parkin has 
been shown to maintain mtDNA integrity and supports mtDNA repair (Rothfuss et al., 2009). 
Another study reported an impact of parkin on mitochondria: in neuroblastoma cells, 
expression of wildtype parkin attenuated reactive oxygen species (ROS) production while the 
mutant protein enhanced ROS formation and apoptosis in these cells (Kuroda et al., 2006). 
How can parkin protect cells from stress-induced apoptosis? Different pathways have been 
suggested to confer parkin-dependent cytoprotectivity. The impact of parkin on several 
signaling pathways has been demonstrated. In particular, parkin negatively regulates the 
c-Jun N-terminal kinase (JNK) pathway (Cha et al., 2005, Jiang et al., 2004, Liu et al., 2008). 
Another study presents evidence that parkin delays endocytosis and degradation of the 
epidermal growth factor receptor (EGFR) by ubiquitination of Eps15, thus promoting 
prosurvival EGF signaling through the PI3K/AKT pathway (Fallon et al., 2006b). Parkin might 
also contribute to the stress-induced activation of the nuclear factor kappa B (NF-B) 
signaling pathway via ubiquitination of NEMO (NF-B essential modifier) and TRAF2 (TNF 
receptor-associated factor 2) (Henn et al., 2007). Moreover, parkin could directly act on 
mitochondria as it is able to reduce the release of cytochrome c from mitochondria during 
cellular stress conditions (Berger et al., 2009). Recently, it has been demonstrated that 
parkin functions in mitophagy, the selective degradation of mitochondria via autophagy 
((Narendra et al., 2008); see also next section 1.5.2). However, it is not clear if mitophagy 
can fully explain the protective capacity of parkin or if these functions are mediated via 
separate pathways. 
 
1.5.2 Parkin mediates the removal of damaged mitochondria via mitophagy 
Parkin is an E3 ubiquitin ligase, mediating the specificity of substrate protein ubiquitination. 
Although several substrates for parkin have been proposed, the validity of these remains 
elusive in vivo. Although it has been recognized for quite a while that parkin exhibits a 
broad-spectrum cytoprotective activity, the exact cellular function of parkin still remains 
obscure. A breakthrough in our understanding of parkin function was derived from a series of 
elegant cell biological studies: the identification that parkin mediates the selective removal of 
dysfunctional mitochondria has strengthened the link between PD pathogenesis and 
mitochondrial dysfunction (Narendra et al., 2008). The group of Richard Youle observed that 
parkin is targeted to mitochondria when the mitochondrial membrane potential is dissipated 
by the uncoupling reagent carbonyl cyanide 3-chlorophenylhydrazone (CCCP). Strikingly, 
upon prolonged exposure to CCCP, mitochondria are cleared from parkin-expressing cells 
within 24 h as determined by immunostaining against several mitochondrial marker proteins. 
The degradation is specific for mitochondria, as peroxisomal abundance and distribution are 
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not changed. Mitophagy is dependent on autophagy: first, inhibition of lysosomal degradation 
by chemical inhibitors blocks the removal of defective mitochondria from the cells. In 
agreement with this, dysfunctional mitochondria are not degraded in autophagy-deficient 
fibroblasts (Narendra et al., 2008, Chan et al., 2011). 
The initial study on mitophagy did not answer the question how parkin might be able to sense 
dysfunctional mitochondria for their selective degradation. Prompted by genetic interaction of 
parkin and PINK1 in Drosophila (Clark et al., 2006, Park et al., 2006, Yang et al., 2006a) and 
indications of an interaction of the two proteins in mammalian cells (Kim et al., 2008, Sha et 
al., 2010, Exner et al., 2007, Shiba et al., 2009, Um et al., 2009), the effect of PINK1 on 
parkin-dependent mitophagy was assessed. Several research groups demonstrated that 
PINK1 recruits parkin to dysfunctional mitochondria (Geisler et al., 2010a, Jin et al., 2010, 
Lazarou et al., 2012, Matsuda et al., 2010, Meissner et al., 2011, Narendra et al., 2010b, Shi 
et al., 2011, Vives-Bauza et al., 2010). Upon uncoupling of the mitochondrial membrane 
potential, full-length PINK1 is stabilized at mitochondria. This is most likely due to inhibited 
mitochondrial import of PINK1 through the TIM/TOM complex and impaired cleavage by the 
presenilin-associated rhomboid-like (PARL), a voltage-dependent mitochondrial protease 
(see (Lazarou et al., 2012) and references above). 
Since the initial discovery of parkin-mediated mitophagy a lot of emphasis has been taken to 
dissect the molecular mechanisms of this pathway. A variety of other factors have been 
implicated in parkin-mediated mitophagy, most notably mitochondrial proteins such as 
voltage-dependent anion channel 1 (VDAC1) and the mitofusins 1 and 2, as well as proteins 
involved in autophagy such as p62, LC-3, Nix, HDAC6 and Ambra1 (Narendra et al., 2010a, 
Geisler et al., 2010a, Chan et al., 2011, Ding et al., 2010, Lee et al., 2010, Okatsu et al., 
2010, Ziviani et al., 2010, Van Humbeeck et al., 2011). However, not all players and steps in 
mitophagy have been elucidated. Most notably, the in vivo relevance of parkin and PINK1 
function in mitophagy is not yet clear, thus it remains to be determined if mitophagy plays a 
role in PD pathogenesis. 
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Figure 7: Sequential steps of parkin-induced mitophagy. On healthy mitochondria, steady-state levels of 
PINK1 are kept low due to rapid shedding, and parkin is mainly found in the cytosol. Upon dissipation of the 
mitochondrial membrane potential, for instance by treatment with the uncoupling agent CCCP, proteolytic 
processing of PINK1 is abolished, resulting in accumulation of full-length PINK1 at the outer mitochondrial 
membrane OMM). PINK1 stabilization is essential to recruit parkin to uncoupled mitochondria, possibly via a 
direct or indirect interaction between PINK1 and parkin. Parkin-induced ubiquitination of OMM proteins allows 
remodeling of the mitochondrial surface, facilitating the recruitment of adaptor proteins that link damaged 
mitochondria to the autophagic machinery. Dysfunctional mitochondria are engulfed in autophagosomes and can 
be degraded after fusion with lysosomes. Figure adapted from (Pilsl and Winklhofer, 2011). 
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1.6 Molecular interaction of parkin and PINK1 
The most compelling link between the PD genes PINK1 and parkin emerged from studies in 
Drosophila. Flies deficient for parkin or PINK1 display similar phenotypes, including abnormal 
mitochondrial morphology, male sterility and apoptotic flight muscle degeneration (Clark et 
al., 2006, Park et al., 2006, Yang et al., 2006a, Greene et al., 2003). Surprisingly, 
overexpression of parkin in PINK1 mutant flies was able to restore the PINK1 mutant 
phenotype, while PINK1 could not compensate for a parkin loss-of-function. These findings 
suggest that PINK1 and parkin function in a common pathway with parkin acting downstream 
of PINK1. In cellular models, silencing of parkin or PINK1 by RNA interference causes similar 
mitochondrial alterations (Lutz et al., 2009, Exner et al., 2007, Sandebring et al., 2009). 
Subsequent analysis in mammalian cells found that parkin was able to rescue mitochondrial 
fragmentation induced by the loss of PINK1 (Exner et al., 2007). 
Supporting evidence for a common parkin-PINK1 pathway originated from the work of 
several groups reporting a direct physical interaction of the two proteins (Kim et al., 2008, 
Sha et al., 2010, Shiba et al., 2009, Um et al., 2009, Moore, 2006). Most studies rely on 
protein overexpression, however, in an approach to analyze the interaction of parkin and 
PINK1 in vivo, endogenous parkin and PINK1 was co-immunoprecipitated in lysates from the 
striatum and substantia nigra of rats (Um et al., 2009) or human brain (Sha et al., 2010). 
However, the direct interaction of the two proteins is not a common finding. It is possible that 
parkin and PINK1 only interact upon particular cellular stress conditions or that the proteins 
function in the same pathway, but their interaction is not direct (Vives-Bauza et al., 2010, 
Lazarou et al., 2012). 
As pointed out before, parkin and PINK1 are both essential for mitophagic degradation of 
mitochondria. Furthermore, parkin and PINK1 share the ability to protect cells from 
stress-induced aptosis. However, it remains to be determined if 1) the protective activities of 
parkin and PINK1 depend on each other and 2) if mitophagy is essential for the 
cytoprotection mediated by parkin and PINK1. 
1.7 Cellular quality control mechanisms 
Protein homeostasis is essential for proper cellular function. Thus, different strategies are 
exploited to keep a proper balance in cellular components. Consequently, already the 
expression of proteins is tightly regulated, with control mechanisms at the level of 
transcription and translation. To achieve a proper tertiary structure, the proteins are then 
folded with the help of chaperones. Misfolded proteins that fail to adopt a native conformation 
are recognized and instantly degraded to prevent potential detrimental effects for the cell. 
Two major pathways are responsible for decomposition of cellular components: the ubiquitin-
proteasomal pathway (UPS) and autophagy. While the UPS is mainly involved in the 
degradation of short-lived and small proteins, the autophagy pathway has been implicated in 
degradation of large proteins, cellular protein aggregates and even whole organelles. 
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Although both pathways work independently and in parallel to each other, they are closely 
linked and are able to functionally compensate each another. 
1.7.1 Ubiquitin-proteasomal system 
The ubiquitin-proteasomal system (UPS) is an essential cellular pathway for protein 
degradation. Degradation of a protein via the UPS involves the covalent attachment of 
ubiquitin chains followed by recognition of the ubiquitinated protein by the proteasome and 
subsequent proteolysis (Figure 8). Ubiquitination of substrate proteins is mediated by a three 
step mechanism: first, an E1 ubiquitin activation enzyme covalently binds an ubiquitin moiety 
in an ATP-dependent manner. Second, the ubiquitin moiety is transferred to an E2 ubiquitin 
conjugation enzyme. In the last step, an E3 ubiquitin ligase controls for specificity of 
substrate ubiquitination. Several rounds of this ubiquitination steps follow to prolong the 
ubiquitin chain and result in polyubiquitination of the substrate protein. Several different 
modes of ubiquitination are used, depending on the lysine residue used to connect the 
different ubiquitin moieties. In particular, linkage via lysine-48 (K48) is a classical signal for 
proteasomal degradation. Substrates ubiquitinated through K48 are recognized by the 
proteasome, unfolded and eventually degraded, while ubiquitin is cleaved off and recycled. 
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Figure 8: Ubiquitin cycle and proteasomal degradation. Substrate ubiquitination is achieved by three 
sequential steps: an E1 ubiquitin activating enzyme covalently binds ubiquitin in an ATP-dependent manner. 
Ubiquitin is then transferred to an E2-conjugating enzyme and subsequently attached to the substrate via an E3 
ubiquitin ligase. The E3 ligase mediates substrate specificity. Ubiquitin can be detached from the substrate 
through a deubiquitinase (DUB). Alternatively, following several rounds of ubiquitination, the substrate can be 
targeted for proteasomal degradation. This involves unfolding of the substrate protein, uptake into the 
proteasome, and cleavage therein. Ubiquitin is detached from the substrate and recycled. 
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1.7.2 Autophagosomal-lysosomal system 
Autophagy has long been classified as a bulk degradation process. Only recently it became 
clear that besides starvation- or stress-induced autophagy, several modes of selective 
autophagy are employed by cells. This includes the selective degradation of pathogens 
(xenophagy), endoplasmic reticulum (reticulophagy), peroxisomes (pexophagy) and 
mitochondria (mitophagy). Autophagy comprises the formation of a phagophore, a 
double-membrane structure, which engulfs the organelle or cargo determined to be degraded 
and forms the autophagosome. Subsequently, the autophagosome fuses with a lysosome, 
following the degradation of the vesicular content by acidic lysosomal proteases (Figure 9). 
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Figure 9: Autophagosomal-lysosomal pathway. During autophagy, a phagophore is formed which engulfs 
cytoplasmic content determined for degradation. Following formation of the autophagosome, the vesicle fuses 
with a lysosome and the intravesicular content is degraded by lysosomal proteases. 
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Interestingly, the substrate recognized for degradation by selective autophagy is tagged by 
ubiquitin molecules. Similarly to the UPS, polyubiquitination serves as a versatile degradation 
signal for selective autophagy. Substrates such as dysfunctional or surplus organelles are 
labeled by ubiquitin. The polyubiquitin signal can subsequently be recognized by autophagy 
adaptor proteins. Autophagy adaptors mediate simultaneous binding of ubiquitinated cargo 
and components of the autophagic machinery. Several adaptor proteins have been identified 
in yeast and in mammalian cells (reviewed in (Behrends and Fulda, 2012)). All of them are 
characterized by an ubiquitin-binding domain, and mammalian examples are neighbor of 
BRCA1 gene 1 (Nbr1), optineurin (OPTN), NIP3-like protein X (NIX) and p62 (also known as 
sequestosome-1 or SQSTM1). The p62 protein contains an ubiquitin-associated domain 
(UBA) involved in ubiquitin binding and a LC3-interacting region (LIR) for interaction with 
autophagosomes (Figure 10).  
 
 
Figure 10: Modular structure of p62. The p62 protein contains an N-terminal PB1 domain important for p62 
auto-oligomerization. The C-terminal ubiquitin-associated domain is involved in polyubiquitin binding. In addition, 
p62 has been shown to interact with TRAF6 (via the TRAF6-binding domain (TB)), which is implicated in NF-B 
signaling. The ZZ domain is a zinc finger domain, and the LC-3 interacting domain (LIR) mediates the binding of 
p62 to autophagosomes via LC3 during selective autophagy. 
 
It has been demonstrated that p62 plays a role in the degradation of protein aggregates. 
Aggregates of mutant huntingtin are encompassed by p62 and degraded by autophagy in a 
p62-dependent manner (Tung et al., 2010). In addition there is a possible role for p62 in 
mitophagy (Ding et al., 2010, Geisler et al., 2010a, Lee et al., 2010), although the 
experimental results obtained from different groups are ambiguous (Narendra et al., 2010a, 
Okatsu et al., 2010). Results from animal models unveil the critical role of selective 
autophagy for cellular homeostasis: mice deficient for p62 display mature-onset obesity, 
insulin resistance, and neurodegeneration (Rodriguez et al., 2006, Ramesh Babu et al., 
2008). Additionally, mutations in p62 have been implicated in Paget’s disease, a chronic 
disorder of the adult characterized by abnormal bone formation (Hocking et al., 2002, Laurin 
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et al., 2002). Of note, p62 is also used as a marker to stain for protein aggregates in a variety 
of proteinopathies, including neurodegeneration conditions, further implying a crucial role of 
selective autophagy in the pathogenesis of protein aggregation diseases (Zatloukal et al., 
2002, Kuusisto et al., 2008, Kuusisto et al., 2001). 
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2 Aims of the thesis 
 
The PD-associated E3 ubiquitin ligase parkin is involved in different cellular processes 
(Figure 11). Many lines of evidence indicate that parkin displays broad neuroprotective 
activity, although the underlying mechanisms are largely unknown. A landmark publication by 
the group of Richard Youle identified parkin as a mediator of mitophagy, the degradation of 
dysfunctional mitochondria via autophagy (Narendra et al., 2008). Although several factors 
contributing to mitophagy have been identified recently, there are still a lot of open questions. 
Analysis of parkin function in mitophagy is of great importance as mitochondrial dysfunction 
is thought to play a key role in PD pathology. In this context it remains to be determined if 
PD-associated mutations in parkin can affect mitophagy and how their function is 
compromised when parkin is mutated. Do pathogenic parkin mutations display a 
loss-of-physiological function in mitophagy? Or is it a toxic gain-of-function mechanism that is 
relevant for the disease? Parkin is an aggregation-prone protein, and several parkin mutants 
tend to misfold and form cellular aggregates. The goal of the second part of this thesis was to 
analyze how aggregates of mutant parkin can be degraded and to characterize the factors 
that contribute to the removal of misfolded parkin conformers. 
 
The results are subdivided into two topics pursuing the following goals: 
 
1. To get insights into the physiological function of parkin and its role in the degradation 
of dysfunctional mitochondria via mitophagy. 
 
2. To investigate the degradation mechanism of pathogenic misfolded parkin mutants. 
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Figure 11: Physiological function and pathological dysfunction of parkin. Parkin is implicated in the 
degradation of dysfunctional mitochondria via mitophagy and mediates cellular stress-protection from apoptotic 
stimuli. Parkin function can be compromised by pathogenic mutation or upon exposure to severe cellular stress. 
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3 Results 
3.1 Characterization of parkin-mediated mitophagy 
3.1.1 Depolarization of mitochondrial membrane potential induces 
mitochondrial fragmentation independently of parkin 
Mitochondria are the cellular powerplants, supplying cells with energy in form of adenosine 
triphosphate (ATP). Maintenance of mitochondrial membrane potential is essential for proper 
mitochondrial function. When mitochondrial membrane potential is lost, dysfunctional 
mitochondria have to be removed by selective autophagy, a process termed mitophagy. The 
mitochondrial membrane potential can be experimentally dissipated by the use of uncoupling 
agents, such as the protonophore CCCP. When cells are treated with CCCP, a rapid 
depolarization of mitochondrial membrane potential is triggered, resulting in the 
fragmentation of the tubular mitochondrial network (Figure 12). This fragmentation in 
response to uncoupling of mitochondrial membrane potential is observed in a variety of 
different cells. Of note, it is independent of parkin as it occurs in HeLa cells that lack 
endogenous parkin. 
 
3.1.2 Parkin is recruited to dysfunctional mitochondria and initiates their 
degradation
Previous studies have shown that parkin is able to translocate to mitochondria that have lost 
their membrane potential and can initiate their degradation via mitophagy (Narendra et al., 
2008). In order to reproduce these findings, HeLa cells were used as they are devoid of 
endogenous parkin (see (Narendra et al., 2008) and own unpublished observations). HeLa 
cells stably expressing human wildtype parkin were obtained by lentiviral transduction. After 
treatment of the cells with the uncoupling reagent CCCP for 1 or 24 h, the cells were fixed 
and subjected to immunofluorescence or Western blotting for mitochondrial marker proteins. 
Parkin was found in the cytosol under basal conditions. Following 1 h of CCCP treatment, 
parkin translocated to mitochondria as assessed by single cell analysis (Figure 12). While all 
control cells retained their mitochondrial staining at 24 hours of CCCP treatment, about two 
third of parkin-expressing cells completely lost mitochondrial staining (Figure 13). Analysis of 
whole cell lysates by Western blotting revealed a strong overall decrease in mitochondrial 
mass in cells parkin-expressing, while there was only a slight decrease in control cells 
lacking parkin (Figure 13). Protein levels of TOM20, a marker protein located in the outer 
mitochondrial membrane, slightly decreased upon 3 h of CCCP treatment in cells expressing 
parkin and even further decreased upon prolonged exposure to CCCP. Similar results were 
obtained with TIM44, a protein associated with the inner mitochondrial membrane. TIM44 
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protein levels decreased upon uncoupling of mitochondrial membrane potential only in 
parkin-expressing HeLa cells, but not in control cells lacking parkin protein. Protein levels of 
the endoplasmic reticulum (calnexin) and the cytoplasm (GAPDH) did not change in 
response to mitochondrial uncoupling and parkin expression (Figure 13).  
 
 
 
Figure 12: Parkin translocates to dysfunctional mitochondria and initiates their degradation. HeLa cells 
stably expressing human wildtype parkin and non-transduced control cells were treated with 10 μM of CCCP for 
the indicated time periods. Cells were subjected to indirect immunofluorescence with the parkin-specific antibody 
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PRK8 (red) and the mitochondria-specific antibody TOM20 (green). DAPI was used for nuclear counterstaining. In 
the last panel, one cell with complete loss of mitochondrial staining is highlighted by a white line to visualize cell 
borders. Note that parkin is sometimes degraded in conjunction with mitochondria, leading to a decrease in parkin 
staining. 
 
 
 
 
Figure 13: Parkin mediates the removal of dysfunctional mitochondria. Left panel: quantification of HeLa 
cells with no mitochondrial staining at 24 h of CCCP (10 μM) treatment. At least 500 cells were manually counted 
in three independent experiments (control: non-transduced HeLa cells, parkin: HeLa cells stably expressing 
wildtype parkin; - : no treatment, + 24 h treatment with 10 μM CCCP). Note that in the absence of parkin or 
CCCP, mitochondria are not degraded. Right panel: immunoblot analysis of HeLa cells stably expressing wildtype 
parkin and untransduced control cells. Cells were treated with 10 μM of CCCP for the indicated times and 10 μg 
of total protein were analyzed for the expression levels of mitochondrial proteins. Parkin expression was assessed 
in parallel and the endoplasmic reticulum marker protein calnexin and the cytosolic GAPDH served as loading 
controls. 
 
3.1.3 Uncoupling of mitochondrial membrane potential but not other cellular 
stressors mediate parkin recruitment to mitochondria and mitophagy 
Parkin has been shown to protect cells from a variety of toxic insults. Apoptosis can be 
prevented by parkin when a broad range of cellular stressors is applied. It is largely unknown 
how parkin mediates its protective activity. To determine if the induction of mitophagy can 
explain the anti-apoptotic function of parkin, a set of different cellular toxins was tested and 
parkin recruitment to mitochondria and subsequent mitophagy was assessed. SH-SY5Y 
neuroblastoma cells were chosen as they biochemically resemble dopaminergic neurons, 
thus expressing a subset of neuronal receptors and being responsive to treatment with 
various neurotoxins. Stable cell lines overexpressing human wildtype parkin were obtained 
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through lentiviral transduction. The protonophore CCCP, which induces mitochondrial 
uncoupling, was used as a positive control. Similar to CCCP, valinomycin (a potassium 
ionophore) treatment resulted in mitochondrial fragmentation followed by a strong and robust 
recruitment of parkin to mitochondria (Figure 14). Oligomycin, an inhibitor of the 
mitochondrial ATP synthase, induced parkin translocation to mitochondria only in a small 
subset of cells (less than 1 % of parkin-expressing cells). However, at 24 h of oligomycin 
treatment, no cells without mitochondria were detected, thus oligomycin treatment did not 
induce parkin-mediated mitophagy. Other stressors tested did not induce parkin translocation 
to mitochondria, neither after 3 h nor after 24 h of treatment (Figure 14 and Figure 15). 
Consequentially, mitochondria were not removed from the cells by mitophagy. Application of 
iron ions (5 mM of iron(III) citrate (Fe3+) or 5 mM of iron(II) chloride (data not shown)) 
resulted in a marginal hyperelongation of mitochondria, but did not effectuate parkin 
translocation or mitophagy (Figure 14Figure 15). Similarly, two PD-associated toxins, 
1-methyl-4-phenylpyridinium (MPP+; 1 mM) and paraquat (1 mM) did not have an effect on 
parkin subcellular distribution and mitochondrial degradation. MPP+ is an inhibitor of 
complex I of the mitochondrial respiratory chain, while paraquat results in increased oxidative 
stress and free radical production. The excitotoxin glutamate (1 mM) and the 
sarcoplasmic/endoplasmic reticulum calcium ATPase-inhibitor (SERCA) thapsigargin (1 mM) 
both cause cellular toxicity by increasing intracellular calcium concentrations. Treatment of 
parkin-expressing SH-SY5Y cells with these chemicals did not result in parkin relocation to 
mitochondria and did not induce mitophagy. In conclusion, parkin translocation to 
mitochondria is only elicited by ionophores that directly depolarize mitochondrial membrane 
potential. In contrast, cellular stressors that directly or indirectly affect mitochondrial function 
do not alter the cytosolic distribution of parkin protein and do not elicit mitophagy.     
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Figure 14: Uncoupling of mitochondrial membrane potential induces parkin translocation from the cytosol 
to mitochondria. SH-SY5Y neuroblastoma cells stably expressing wildtype parkin were treated with the indicated 
chemicals for 3 h. Cells were subsequently stained with the parkin-specific antibody PRK8 (red) and the 
anti-TOM20 antibody (green) to visualize mitochondria.
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Figure 15: Uncoupling of mitochondrial membrane potential induces parkin-mediated mitophagy. SH-
SY5Y cells stably expressing wildtype parkin were treated with the indicated chemicals for 24 h. Cells were 
stained with the parkin-specific antibody PRK8 (red) and the anti-TOM20 antibody (green) to visualize 
mitochondria. Representative single cells with no mitochondrial staining were surrounded by a white line to depict 
mitophagy. 
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3.1.4 Pathogenic parkin mutants are compromised in mitochondrial 
translocation or mitophagy completion 
Several mutations in the parkin gene have been linked to autosomal recessive early-onset 
PD. The disease-causing mutations are distributed all over the parkin gene, but cluster in the 
functional domains of the protein. Different pathogenic parkin mutations have been identified, 
ranging from single point mutations to truncating mutations and large genomic 
rearrangements. Therefore it was important to analyze the effect of parkin mutations on its 
ability to translocate to mitochondria and initiate mitophagy. To this aim, pathogenic parkin 
mutants were transiently expressed in HeLa cells and parkin recruitment and mitophagy 
were assessed at 1 and 24 h of CCCP treatment. In contrast to wildtype parkin which is 
cytosolic under basal conditions, several parkin mutants showed a spotted, aggregate-like 
staining (Figure 16). In particular, the cysteine point mutants C212Y and C289G and the 
truncation mutants W453X and E409X displayed cytosolic aggregates that did not colocalize 
with mitochondria. In addition, these mutants lacked the ability to translocate to mitochondria 
when the mitochondrial membrane potential was uncoupled. Contrarily, the G340D 
pathogenic parkin mutant showed a cytosolic staining pattern analogous to wildtype parkin. 
However, when cells expressing the G430D parkin mutant were treated with CCCP, the 
protein did not redistribute to mitochondria. Even upon prolonged exposure to CCCP, G430D 
parkin remained cytosolic and did not translocate to the fragmented, dysfunctional 
mitochondria. The analysis of different point mutations located in the ubiquitin-like domain 
(UBL) of the parkin protein yielded similar results for all mutants analyzed: first, the mutant 
protein was soluble under basal conditions with no appearance of aggregates. Second, upon 
treatment of the cells with CCCP, all parkin UBL mutants displayed translocation to 
mitochondria, although to different extents. Upon treatment with CCCP for 24 h, mitophagy 
was initiated by means of all parkin UBL mutants (Figure 17). These results suggest that the 
parkin UBL domain might be dispensable for parkin mitochondrial recruitment and 
mitophagy. Furthermore, some parkin mutants might be inactivated through their propensity 
to misfold and aggregate formation (Figure 16). 
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Figure 16: Pathogenic parkin mutants are compromised in mitochondrial translocation or mitophagy. 
HeLa cells were transiently transfected with the indicated parkin mutants and treated with 10 μM CCCP for 1 h. 
Parkin was visualized using the PRK8 antibody (green) and mitochondria with the anti-TOM20 antibody (red). 
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Figure 17: Pathogenic mutations in the UBL domain of parkin do not interfere with mitophagy. HeLa cells 
were transfected with the indicated parkin mutants (all located in the UBL domain of parkin (amino acids 1 to 76)) 
and treated with 10 μM of CCCP for 1 h. Cells were immunostained with the parkin-specific antibody PRK8 
(green) and the mitochondria-specific TOM20 (red) antibody. A white line surrounds single cells devoid of 
mitochondrial staining. 
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3.1.5 Deletion of parkin functional domains results in parkin insolubility and 
loss of mitochondrial translocation and mitophagy 
Parkin is an E3 ubiquitin ligase composed of an N-terminal UBL domain and a C-terminal 
RBR domain. The RBR domain consists of two RING domains separated by an IBR domain. 
To test which domains are required for parkin function in mitophagy, individual domain 
deletion mutants were transiently expressed in HeLa cells and mitochondrial recruitment of 
parkin and mitophagy were evaluated upon uncoupling of the mitochondrial membrane 
potential. In untreated cells, wildtype parkin was homogenously distributed throughout the 
cytosol (Figure 18). The UBL mutant lacking the first 76 N-terminal amino acids also 
appeared cytosolic under basal conditions. In contrast, all other parkin domain deletion 
mutants showed a punctuate staining pattern in the cytosol, suggesting that proper parkin 
folding is impaired by the deletion of C-terminal domains. Next, CCCP was added for 1 h to 
assess the recruitment of the parkin mutants to uncoupled mitochondria. Wildtype parkin as 
well as the UBL mutant colocalized with mitochondria, and upon 24 h of CCCP exposure, 
mitochondria were degraded under these conditions. Contrarily, deletion of any other domain 
impaired mitochondrial translocation of parkin and compromised mitophagy, resulting in no 
clearance of mitochondria via mitophagy. In concordance with the analysis of pathogenic 
parkin mutants (Figure 17), the UBL domain of parkin seems to be dispensable for 
mitophagy, while all other domains seem essential for parkin folding and function in 
mitochondrial removal. 
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Figure 18: The UBL domain of parkin is dispensable for mitochondrial recruitment of parkin, all other 
domains are essential. HeLa cells were transiently transfected with the indicated parkin species: UBL (deletion 
of amino acids 1-76), linker (77-237), RING1 (238-293), IBR (314-377), RING2 (418-449). CCCP was 
added for 1 h and cells were analyzed by indirect immunofluorescence for parkin subcellular distribution and 
colocalization of parkin and mitochondria. The PRK8 parkin-specific antibody (green) and an anti-TOM20 
mitochondria-specific antibody (red) were used for immunofluorescence stainings. 
Results 
45 
 
 
3.1.6 Parkin-dependent ubiquitination of depolarized mitochondria 
Ubiquitination serves as a signal for various cellular signaling pathways, including targeting 
of substrates for degradation via the proteasome or through selective autophagy. Parkin is 
an E3 ubiquitin ligase, mediating substrate specificity of ubiquitination. Thus, ubiquitination of 
mitochondrial proteins could trigger parkin-mediated mitophagy. To test this hypothesis, 
HeLa cells stably expressing wildtype parkin were treated with CCCP for 1 h and analyzed 
for colocalization of parkin and polyubiquitin or mitochondria and polyubiquitin. Polyubiquitin 
signal, as analyzed by an antibody recognizing chains that consist of three or more ubiquitin 
moieties (polyubiquitin-antibody clone FK1), revealed staining throughout the cells with 
highest intensity in the cytoplasm (Figure 19). Remarkably, general staining intensity was 
greatly enhanced when cells were treated with CCCP for 2 h. In addition, the polyubiquitin 
signal strongly colocalized with both depolarized mitochondria and parkin. However, an 
enhanced polyubiquitin signal was only observed in cells expressing parkin, suggesting that 
parkin is either directly or indirectly involved in the assembly of polyubiquitin chains at 
mitochondria. 
A single ubiquitin moiety contains seven lysine residues that can be employed for the 
assembly of polyubiquitin chains. Dependent on which lysine residue is used to connect 
single moieties, different signaling pathways or responses can be triggered. In particular, 
linkage of lysine-48 (K48 ubiquitin) is a signal for proteasomal degradation, while linkage via 
lysine-63 (K63 ubiquitin) is involved in selective autophagy. Specific antibodies have been 
developed that are able to distinguish K48- and K63-linked polyubiquitin. In order to address 
the questions which polyubiquitin linkage is found in the parkin-mediated mitophagy pathway, 
these antibodies were used in indirect immunofluorescence. Interestingly, both K48- and 
K63-linked polyubiquitin chains were found to colocalize with mitochondria when membrane 
potential was dissipated (Figure 20). The analysis of parkin revealed that both K48- and 
K63-specific ubiquitin signal was observed to colocalize with parkin and increased intensity 
of both markers was determined when mitochondrial membrane potential was lost. 
Interestingly, polyubiquitin staining was increased only in cells expressing parkin, but 
remained at baseline in the absence of parkin (Figure 20 and data not shown). 
Consequently, the results presented above point towards a role of parkin in the ubiquitination 
of mitochondrial substrate/s, either directly or via a so far unknown indirect pathway.   
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Figure 19: Increased polyubiquitin reactivity at mitochondria in the presence of parkin upon uncoupling 
of mitochondrial membrane potential. HeLa cells stably expressing wildtype parkin were treated with CCCP for 
2 h. Upper panel: Immunofluorescence staining of total polyubiquitin (clone FK1; red) and mitochondria (TOM20; 
green). Note that polyubiquitin signal at mitochondria is enhanced upon CCCP treatment. Lower panel: 
Immunofluorescence staining of total polyubiquitin (clone FK1; red) and parkin (PRK8; green). Notably, ubiquitin 
staining is selectively enhanced in cells expressing parkin (see lower right picture). 
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Figure 20: K48- and K63-linked polyubiquitin staining at mitochondria upon loss of mitochondrial 
membrane potential. HeLa cells stably expressing wildtype parkin were treated with CCCP for 2 h. Upper panel 
(previous page): Immunofluorescence staining of polyubiquitin (K48-linked ubiquitin (Apu2; red; rows 1 and 2) and 
K63-linked ubiquitin (Apu3; green; rows 3 and 4)) and mitochondria (TOM20; green). Note that polyubiquitin 
signal at mitochondria is enhanced upon CCCP treatment. Lower panel: Immunofluorescence staining 
polyubiquitin (K48-linked ubiquitin (Apu2; green; rows 1 and 2) and K63-linked ubiquitin (Apu3; green; rows 3 and 
4)) and parkin (PRK8; red). Notably, ubiquitin staining is selectively enhanced in cells expressing parkin and 
colocalizes with parkin. 
 
3.1.7 Both autophagy and proteasomal degradation are essential for 
mitophagy 
The previous results pointed out, that both K48- and K63-linked polyubiquitin chains are 
involved in labeling dysfunctional mitochondria for degradation via parkin-dependent 
mitophagy. As K48-linked polyubiquitin is a bona fide signal for proteasomal degradation, but 
not autophagy, it is important to investigate the contribution of the UPS and the autophagy 
pathway on mitophagy. In a first approach, embryonic fibroblasts from mice lacking ATG5 
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(ATG5 KO MEF) and corresponding wildtype mice were chosen to see if functional 
autophagy is required for parkin-mediated mitochondrial removal. ATG5 is a core component 
of the autophagic pathway and essential for autophagosome formation. Fibroblasts from 
ATG5 KO mice lost their ability to implement autophagy. To see if mitophagy was impaired in 
these cells, ATG5 KO MEFs and corresponding wildtype fibroblasts were stably transduced 
with wildtype parkin by lentiviral transduction. Cells were treated with 10 μM of CCCP for 1 h 
to investigate parkin recruitment to mitochondria and for 24 h to quantify mitophagy. 
Following 1 h of mitochondrial uncoupling, parkin robustly redistributed from the cytosol to 
mitochondria both in wildtype and ATG5-deficient cells (Figure 21). Similar results were 
obtained when HSP60, a mitochondrial matrix protein, was used to stain mitochondria 
instead of TOM20. However, when cells were analyzed for mitophagy after 24 h of CCCP 
treatment, the results varied depending on which mitochondrial marker protein was used. In 
wildtype control MEFs expressing parkin, mitochondrial staining was lost in about half of the 
cell population, with no significant difference between the different mitochondrial stainings. In 
contrast, while mitophagy appeared to be induced when TOM20 was used to stain 
mitochondria, no mitophagy was observed when HSP60 was utilized. TOM20 is an outer 
mitochondrial membrane protein, thus it is possible that outer mitochondrial membrane 
proteins are degraded independently of autophagy, explaining the contradicting results 
obtained with the different mitochondrial markers. 
 
 
 
 
Figure 21: Mitophagy, but not mitochondrial recruitment of parkin is compromised in autophagy-deficient 
cells. Wildtype and ATG5 KO MEF cells were stably transduced to express human wildtype parkin. Cells were 
treated with 10 μM of CCCP for 1 h (left graph) or 24 h (right graph), respectively. Cells were analyzed for 
colocalization of parkin with mitochondria in immunofluorescence using the mitochondrial marker proteins TOM20 
or HSP60. At 24 h of CCCP treatment, cells devoid of mitochondria were counted and the percentage of cells with 
no mitochondrial staining was quantified.  
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In order to further investigate the role of proteasomal degradation on mitophagy, chemical 
inhibitors were used to block proteasomal or lysosomal function: epoxomycin is a selective 
and covalent inhibitor of the proteasome; bafilomycin A1 is a specific inhibitor of vacuolar-
type H+-ATPase, thereby interfering with lysosomal acidification. Both inhibitors were applied 
to HeLa cells stably expressing wildtype parkin, either separately or in combination with 
CCCP for 1 h and 24 h, respectively. Upon dissipation of mitochondrial membrane potential, 
parkin was recruited to dysfunctional mitochondria within 1 h. Parkin redistribution was not 
altered when proteasomal or lysosomal function were blocked (data not shown). In addition, 
although bafilomycin A1 treatment resulted in a slight fragmentation of mitochondria, it did 
not induce parkin translocation to mitochondria. Epoxomycin treatment did not affect 
mitochondrial morphology, however cell morphology changed and cells elongated upon 
addition of the proteasomal inhibitor. Following treatment with the inhibitors for 24 h, 
parkin-dependent mitophagy was assessed (Figure 22). The percentage of cells with no 
mitochondrial staining was determined in three independent experiments (Figure 23). In the 
absence of CCCP, all cells retained their mitochondrial staining. In line with the previous 
results, blockage of lysosomal function with bafilomycin A1 resulted in an almost complete 
loss of mitophagic activity in the presence of CCCP. Interestingly, inhibition of the 
proteasome with epoxomycin during CCCP treatment also significantly decreased the 
percentage of cells with no mitochondrial staining. In summary, both intact lysosomal and 
proteasomal function appear to be crucial to complete parkin-dependent mitochondrial 
degradation. 
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Figure 22: Mitophagy is compromised by both lysosomal and proteasomal inhibition. HeLa cells stably 
expressing wildtype parkin were treated with bafilomycin A1 (bafA1, 30 nM), epoxomycin (epoxo, 10 nM) or 
CCCP (10 μM) alone, or bafilomycin A1 and epoxomycin were applied in combination with CCCP. After 24 h of 
treatment with the indicated chemicals, cells were fixed and stained for parkin (PRK8; red) and mitochondria 
(TOM20; green). Note that bafilomycin A1 treatment results in a fragmentation of mitochondria but does not 
induce mitophagy. 
Results 
52 
 
 
 
 
Figure 23: Inhibition of proteasomal and lysosomal function impairs mitophagy. HeLa cells stably 
expressing human wildtype parkin were simultaneously treated for 24 h with the indicated inhibitors (CCCP: 10 
μM CCCP, epoxo: 10 nM epoxomycin, bafA1: 30 nM bafilomycin A1). Cells were stained with parkin-specific 
antibody PRK8 and TOM20 antibody to stain mitochondria. The number of cells with no mitochondria was 
counted and the percentage of mitophagy quantified.   
 
3.1.8 PINK1 is essential for parkin-mediated mitophagy 
Experimental evidence from genetic linkage analysis in Drosophila melanogaster suggests 
that the PD-associated protein PINK1 functions in a common pathway with parkin, with 
PINK1 acting upstream of parkin (Clark et al., 2006, Park et al., 2006, Yang et al., 2006a). 
Furthermore, in vitro studies even suggest that parkin and PINK1 might interact directly (Kim 
et al., 2008, Shiba et al., 2009, Um et al., 2009, Moore, 2006). In order to analyze the 
importance of PINK1 on parkin-mediated mitophagy, fibroblasts from mice lacking PINK1 
were used. Both PINK1 KO and corresponding wildtype MEFs were transduced with a 
lentivirus for parkin overexpression. Of note, cells deficient for PINK1 displayed an altered 
mitochondrial morphology, with shortened and fragmented mitochondria. Parkin 
overexpression by lentiviral transduction did not alter mitochondrial morphology in these 
cells, and parkin was not recruited to mitochondria in the absence of mitochondrial 
uncoupling. To assess parkin recruitment and mitophagy in these cells, an immunostaining 
for parkin and the mitochondrial marker TOM20 was conducted after 1 h and 24 h of CCCP 
treatment. As PINK1 is a serine-threonine kinase with a mitochondrial targeting sequence 
(MTS), PINK1 might be involved in the recruitment of parkin to mitochondria. Indeed, while 
parkin readily translocated to mitochondria in wildtype fibroblasts, the protein remained 
cytosolic and was not recruited to mitochondria (data not shown). Even more remarkably, at 
24 h of CCCP treatment, parkin was still completely cytosolic in fibroblasts lacking PINK1 
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and accordingly mitochondria were not degraded (Figure 24). In contrast, mitochondria were 
sequestered in wildtype MEFs in more than 50 % of cells expressing parkin (Figure 24 and 
Figure 25). The results implicate that PINK1 is essential for targeting parkin to dysfunctional 
mitochondria.  
 
 
 
Figure 24: PINK1 is essential for parkin-mediated mitophagy. Wildtype and PINK1 KO MEFs stably 
overexpressing human wildtype parkin were treated with 10 μM CCCP for 24 h. Parkin (PRK8; green) and 
mitochondria (TOM20 polyclonal antibody; red) were stained. Exemplified cells with no mitochondrial staining are 
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surrounded by a white line for better visualization. Picture published in Pilsl & Winklhofer, Acta Neuropathol., 2011 
(Pilsl and Winklhofer, 2011). 
 
 
 
Figure 25: PINK1 is essential for parkin-dependent degradation of dysfunctional mitochondria. Wildtype 
and PINK1 KO mouse fibroblasts stably expressing human wildtype parkin or untransduced cells (control) were 
treated with 10 μM CCCP for 24 h. Cells were immunostained for parkin (PRK8) and mitochondria (TOM20) and 
the percentage of cells with no mitochondrial staining was quantified. Results were obtained from three 
independent experiments with at least 500 cells counted per condition.  
 
3.1.9 Overexpression of parkin and PINK1 is sufficient to induce mitophagy in 
the absence of mitochondrial depolarization 
Analysis of mitophagy in PINK1-deficient cells pointed towards an essential role of PINK1 in 
parkin-dependent mitophagy. Previous studies from other groups suggest that parkin and 
PINK1 might directly interact with each other. It is possible that the mitochondrial protein 
PINK1 can target parkin to dysfunctional mitochondria to initiate their degradation. To further 
investigate the role of PINK1 in mitophagy, HeLa cells were transiently transfected with 
PINK1-V5 and pcDNA3.1 empty vector as a control or together with parkin. Cells were 
allowed to grow for 24 h after transfection, then an immunostaining for PINK1 (detected via 
the C-terminal V5 tag) or parkin (PRK8) and mitochondria (TOM20) was done. 
Overexpression of PINK1 alone resulted in part of the protein in the cytosol and another part 
colocalizing with mitochondria (Figure 26). This is in line with other studies demonstrating 
that PINK1 is partially imported into mitochondria, but can also be found in the cytosol 
(Weihofen et al., 2008, Takatori et al., 2008, Beilina et al., 2005, Haque et al., 2008, Lin and 
Kang, 2008, Lin and Kang, 2010). Mitochondrial morphology was not affected by PINK1 
overexpression, retaining a tubular network. Surprisingly, PINK1 and parkin coexpression 
frequently resulted in the formation of large mitochondrial clusters that colocalized with both 
parkin and PINK1 (data not shown). In addition, a subset of cells displayed no mitochondrial 
staining upon coexpression of parkin and PINK1, suggesting that both proteins can initiate 
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mitochondrial degradation even in the absence of mitochondrial uncoupling (Figure 26). 
Notably, when cells overexpressing PINK1 alone were treated with CCCP, mitochondria 
fragmented but were not degraded, pointing out that PINK1 itself is not sufficient to induce 
mitophagy in the absence of parkin. To determine if mitochondrial targeting of PINK1 is 
crucial for parkin-induced mitophagy, a PINK1 mutant with a deletion of the first 110 
N-terminal amino acids (PINK1110) was analyzed (provided by Kathrin Lutz). This mutant 
lacks the N-terminal mitochondrial targeting sequence (MTS) and the transmembrane 
domain (TM). Indeed, the mutant was expressed and displayed a cytosolic staining pattern 
with no colocalization of the PINK1 mutant and mitochondria (Figure 26). When wildtype 
parkin was coexpressed with PINK1110, it remained cytosolic and was not recruited to 
mitochondria. Furthermore, simultaneous expression of parkin and PINK1110 was not able 
to induce the degradation of mitochondria via autophagy. In summary, PINK1 is responsible 
for parkin recruitment to mitochondria and mitochondrial targeting of PINK1 is crucial for 
mitophagy. Overexpression of PINK1 and parkin is able to induce mitophagy, even when the 
mitochondrial membrane potential is intact. 
 
 
 
Figure 26: PINK1 expression is sufficient to induce parkin-mediated mitophagy. HeLa cells were transiently 
transfected with 0.5 μg of wildtype PINK1 or a mutant lacking 110 N-terminal amino acids (PINK1110); either 0.5 
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μg of pcDNA empty vector control or parkin was cotransfected. Cells were stained with TOM20 to visualize 
mitochondria (red) and either parkin (PRK8; green; rows 2 and 4) or PINK1 (using a V5 monoclonal epitope 
antibody; green; rows 1 and 3). 
 
 
Figure 27: Coexpression of parkin and PINK1 is sufficient to induce mitophagy. HeLa cells were transiently 
transfected with the indicated vectors (0.5 μg each). After 24 h, the cells were fixed and analyzed by indirect 
immunofluorescence using the TOM20 antibody to visualize mitochondria. Transfected cells were analyzed for 
the presence of mitochondrial staining and the percentage of cells devoid of mitochondria was calculated. The bar 
graphs represent the results from three independent experiments with a minimum of 300 cells counted for each 
condition. 
 
3.1.10 Overexpression of PINK1 induces insolubility of parkin 
Previous analysis of the impact of PINK1 on parkin-mediated mitophagy revealed that 
coexpression of parkin and mitochondrially localized PINK1 is sufficient to induce mitophagy. 
However, the mechanism by which PINK1 influences parkin function is not clear. In cells 
where mitochondria were cleared from the cell by concomitant expression of parkin and 
PINK1, parkin appeared to be clustered rather than homogenously distributed throughout the 
cytosol (cf. Figure 26). Notably, parkin is an aggregation-prone protein and is rendered 
insoluble following a variety of cellular insults (see section 1.5). Parkin distribution upon 
coexpression of PINK1 reminded of aggregated parkin, thus the effect of PINK1 on parkin 
solubility was analyzed in a detergent-solubility assay. A mixture of the nonionic detergent 
Triton X-100 and the ionic detergent sodium desoxycholate (both 0.5 % (v/v) in PBS) was 
exploited for the analysis of parkin solubility. To experimentally address this, human 
embryonic kidney (HEK) 293T cells were used. HEK cells are particularly suited for the 
detergent-solubility assay as they are easily transfectable by liposome-mediated transfection 
reagents and show high transfection efficiencies. When parkin was expressed in HEK cells, 
Results 
57 
 
the protein was almost completely detected in the detergent-soluble (S; soluble) fraction 
(Figure 28). Similar results were obtained when the PD-associated protein DJ-1 was 
coexpressed: parkin was soluble in the presence of DJ-1. DJ-1 was chosen as a control as it 
displays a comparable subcellular distribution as PINK1 under certain cellular conditions, 
contains a C-terminal V5-tag and is expressed from the pcDNA6 vector, exactly the same as 
for PINK1. Surprisingly, the solubility of parkin dramatically changed in the presence of 
overexpressed wildtype PINK1. Under these conditions, parkin protein shifted to the 
detergent-insoluble fraction (P; pellet). In addition, PINK1 expression stabilized parkin protein 
levels; total protein levels of parkin were elevated in the presence of PINK1. Remarkably, 
treatment of cells expressing parkin with CCCP for 6 h also induced a partial shift of parkin to 
the detergent-insoluble fraction (Figure 27). Therefore, a conformational shift of parkin, 
reflected in altered detergent-solubility of the protein, could be a possible trigger for 
subsequent mitophagy.  
 
 
 
Figure 28: Overexpression of PINK1 results in parkin insolubility. HEK cells were transiently transfected with 
0.5 μg of wildtype parkin and 0.5 μg of the indicated plasmids (pcDNA: empty vector control; PINK1: 
pcDNA6-PINK1-V5; DJ-1: pcDNA6-DJ-1-V5). Cells were either left untreated or 10 μM CCCP was added for 6 h. 
The cells were subjected to detergent-solubility assay (0.5 % Triton X-100 and 0.5 % desoxycholic acid in PBS) 
and equal amounts of detergent-soluble (S) and –insoluble fraction (P) were analyzed via Western blotting for 
parkin (PRK8 antibody). 
 
3.1.11 Mitochondrial depolarization induces insolubility of parkin 
The previous results showed that PINK1 is able to induce biochemical alterations of the 
parkin protein. Overexpression of PINK1 resulted in a shift of parkin from the 
detergent-soluble to the insoluble fraction (see Figure 28). Furthermore, the experiment 
provided evidence that CCCP treatment does have an effect on parkin solubility. To confirm 
these results, the solubility of parkin was assessed at different time points of CCCP 
treatment. Equal amounts of detergent-soluble and –insoluble fraction (0.5 % (v/v) Triton X-
100 and sodium desoxycholate in PBS) were analyzed via Western blotting for parkin. 
Depending on the duration of CCCP treatment, parkin gradually shifted from the soluble into 
the insoluble subcellular fraction (Figure 29). After 16 h of CCCP application, parkin was 
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rendered completely insoluble, and this effect persisted to 24 h of mitochondrial uncoupling. 
Of note, at this time point, total levels of parkin protein were decreased. This is in accordance 
with investigations of parkin-dependent mitophagy in immunofluorescence, where parkin is 
often found to be degraded concomitantly with mitochondria. Thus, under conditions where 
CCCP is able to induce parkin translocation to mitochondria and mitophagy, a conformational 
shift of parkin is observed.  
 
 
 
Figure 29: Uncoupling of mitochondria membrane potential alters parkin solubility. HEK cells were 
transiently transfected with human wildtype parkin. Following different time periods of treatment of cells with 
10 μM of CCCP as indicated, the solubility of parkin was analyzed. Therefore, cells were lysed in 0.5 % (v/v) 
Triton X-100 and sodium desoxycholate in PBS and separated by centrifugation. Equal amounts of 
detergent-soluble and –insoluble fraction were analyzed by immunoblotting for parkin (PRK8). 
 
3.1.12 In the absence of PINK1 CCCP does not render parkin insoluble 
The experimental data obtained from the above analysis pointed towards a role of parkin 
conformation on mitophagy. Overexpression of PINK1 or treatment of cells with CCCP 
resulted in a change of biochemical properties of parkin protein, with parkin being rendered 
insoluble in detergent. Importantly, these are conditions in which parkin can initiate 
mitochondrial degradation via mitophagy. 
In order to investigate whether endogenous PINK1 has an effect on parkin solubility upon 
exposure to CCCP, parkin solubility in the absence and presence of CCCP was assessed in 
PINK1 KO MEFs. For this purpose, fibroblasts from PINK1 KO mice and wildtype littermates 
were lentivirally transduced to stably overexpress human wildtype parkin. For each genotype, 
fibroblasts from two different animals were used. GFP transduced MEFs served as a control. 
Cells were treated with CCCP for 24 h and subsequently subjected to detergent-solubility 
assay using 0.5 % Triton X-100 and 0.5 % desoxycholic acid (v/v). While GFP was 
consistently found selectively in the detergent-soluble fraction, CCCP was able to induce a 
shift of parkin to the detergent-insoluble fraction in wildtype fibroblasts (Figure 30). In 
contrast, no shift of parkin was observed in MEF cells lacking PINK1. Parallel experimental 
assessment of mitophagy in these cell reproduced previous findings (see Figure 24) that 
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PINK1 is crucial for mitophagy and mitochondria with lost membrane potential are only 
degraded in wildtype, but not in PINK1-deficient cells. Based on these findings it becomes 
evident that PINK1 is essential for recruitment of parkin to dysfunctional mitochondria and 
their subsequent removal by mitophagy. In the absence of PINK1, parkin does not change its 
biochemical properties upon exposure to CCCP and does not shift to the detergent-soluble 
fraction. 
 
 
 
Figure 30: CCCP does not alter parkin solubility in the absence of PINK1. Wildtype and PINK1 KO MEFs 
were stably transduced with human wildtype parkin or GFP as a control. Cells were treated for 3 h with 10 μM 
CCCP, harvested and subjected to detergent solubility assay. Fibroblast cells lines were obtained from two 
different mice and analyzed for parkin solubility (independent MEF lines from independent mouse embryos were 
obtained, left panel: representative immunoblot for wildtype line 1 and PINK1 KO line 1; right panel: same 
representative experiment for line 2). Note that CCCP treatment results in a partial shift of parkin to the 
detergent-insoluble fraction in wildtype, but not in PINK1 KO fibroblasts. GFP, overexpressed as a control protein, 
stays completely soluble under these experimental conditions. 
 
3.1.13 Pathogenic PINK1 mutants have differential effects on parkin solubility 
and mitophagy 
Autosomal recessive mutations in parkin or PINK1 cause PD. The previous results revealed 
that several pathogenic parkin mutants are prone to misfolding and are impaired in 
mitochondrial translocation and mitophagy. To gain insights into the role of pathogenic 
PINK1 mutants in alteration of parkin solubility, the detergent-solubility assay was applied in 
the presence of PINK1 mutants. When DJ-1 was coexpressed with parkin as a control, 
parkin protein was detected in the detergent-soluble fraction. Expression of wildtype PINK1 
resulted in a partial shift of parkin to the pellet fraction (Figure 31). Similar results were 
obtained with a PINK1 mutant lacking a part of the N-terminal bipartite mitochondrial 
targeting signal but retaining the transmembrane (TM) domain (PINK178; deletion of amino 
acids 1 to 78). In immunofluorescence, this PINK1 mutant is largely cytosolic but a subset of 
the protein is able to colocalize with mitochondria, a picture similar to the expression of the 
wildtype PINK1 protein. In contrast, the pathogenic mutant W437X, a truncated PINK1 
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species, did not alter parkin solubility when overexpressed in HEK cells. Similarly, the 
pathogenic point mutants G309P, L347P and Q126P did not result in a shift of parkin to the 
detergent-insoluble fraction. In conclusion, the PINK1 mutants analyzed are defective in 
changing the biochemical properties of parkin in respect to detergent solubility of the protein. 
 
 
 
Figure 31: Pathogenic PINK1 mutants do not affect parkin solubility. HEK cells were transiently transfected 
with 0.3 μg of wildtype parkin and 0.3 μg of the indicated expression constructs. DJ-1 was used as a control. Cells 
were lysed in Triton X-100 and desoxycholic acid (0.5 % (v/v) in PBS) and separated into detergent-soluble and 
-insoluble fraction by centrifugation. Equal volumes of S and P fraction were analyzed by Western blot analysis for 
parkin using the PRK8 antibody.  
3.1.14 Mitochondrially targeted parkin induces mitophagy upon dissipation of 
mitochondrial membrane potential 
As outlined by the experiments above, parkin is recruited to depolarized mitochondria and 
initiates their degradation via mitophagy. Moreover, PINK1 is essential for redistribution of 
parkin to mitochondria, and mitochondrial targeting of PINK1 is crucial for this process. In the 
absence of PINK1, parkin is not targeted to mitochondria and mitochondrial removal is not 
induced. In addition, overexpression of PINK1 recruits parkin to mitochondria and initiates 
mitophagy even in the absence of CCCP treatment. 
To answer the question whether recruitment of parkin is sufficient to induce mitophagy, an 
approach was chosen to directly target parkin to the outer mitochondrial membrane (OMM): 
an artificial vector construct was cloned directly anchoring parkin to the OMM and termed 
mitoparkin. To this aim the mitochondrial targeting sequence and the transmembrane domain 
(TM) of human TOM20 were N-terminally fused to the coding sequence of human wildtype 
parkin. A short linker sequence (6 amino acids) was introduced between the TM domain of 
TOM20 and parkin to allow proper parkin folding and avoid steric hindrance (Figure 32). 
Expression of this construct targets parkin to the outer mitochondrial membrane surface with 
parkin being exposed to the cytosol.  
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Figure 32: Schematic representation of mitoparkin. The artificial fusion protein mitoparkin consists of the first 
40 amino acids of TOM20 (including the MTS and TM domain) followed by a short peptide linker of 6 amino acids 
and the full coding sequence of human wildtype parkin (not drawn to scale). The start codon of parkin was 
removed to avoid expression of untagged wildtype parkin. Mitoparkin is inserted to the outer mitochondrial 
membrane, with parkin facing the cytosol. aa: amino acid.
 
When HeLa cells were transiently transfected with mitoparkin, the artificial fusion protein was 
nicely expressed as determined by immunoblot analysis (Figure 33). Furthermore, it was 
targeted to mitochondria and did not influence mitochondrial morphology when expressed at 
low levels (Figure 34). Notably, expression of mitoparkin did not induce mitophagy per se, 
suggesting that targeting of parkin to functional mitochondria is not sufficient for 
parkin-mediated mitophagy. In addition, parkin is an aggregation-prone protein, and 
anchoring of the protein to mitochondria could interfere with parkin folding and function. To 
determine if the artificial fusion protein mitoparkin was functional, CCCP was added to 
mitoparkin expressing HeLa cells to depolarize mitochondrial membrane potential. Indeed, 
mitoparkin was fully functional and removed dysfunctional mitochondria to the same extent 
than untargeted wildtype parkin (Figure 34). 
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Figure 33: Mitoparkin protein is expressed. HeLa cells were transiently transfected with 0.5 μg of mitoparkin. 
After 24 h, cells were harvested and total lysates were subjected to immunoblot analysis using the parkin-specific 
antibody PRK8.
 
 
 
Figure 34: Mitoparkin localizes to mitochondria. HeLa cells were transiently transfected with mitoparkin and 
analyzed for colocalization of mitoparkin (parkin-specific PRK8 antibody; red) and mitochondria (TOM20 
polyclonal antibody; green). In order to check for the functionality of mitoparkin, cells were treated with 10 μM of 
CCCP for 24 h. As an example, a single cell with no mitochondrial staining is highlighted by a white line, indicating 
the cell borders. Note that the TOM20 antibody does not cross-react with mitoparkin as the antibody was 
generated against a C-terminal fragment of TOM20, which is not present in mitoparkin. 
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3.1.15 Mitochondrial targeting of parkin is not sufficient to induce mitophagy in 
the absence of PINK1  
The analysis of mitoparkin, an artificial fusion protein anchoring parkin to the mitochondrial 
OMM, has shown that mitochondrial targeting of parkin is not sufficient to induce mitophagy 
in the absence of mitochondrial uncoupling. PINK1 has been shown to recruit parkin to 
dysfunctional mitochondria and parkin is not targeted to mitochondria when PINK1 is lacking. 
In order to investigate if PINK1 has additional functions in mitophagy apart from parkin 
mitochondrial recruitment, mitoparkin was subcloned into a lentiviral expression vector to 
obtain stable cell lines by lentiviral transduction. In concordance with the results from HeLa 
cells, mitoparkin expression did not alter mitochondrial morphology and did not induce the 
degradation of mitochondria (Figure 35). As already outlined above, mitochondria are shorter 
and partially fragmented in PINK1-deficient cells compared to wildtype fibroblasts or HeLa 
cells, however, this effect is independent of parkin or mitoparkin expression. 
Surprisingly, when the mitochondrial membrane potential was dissipated by CCCP 
treatment, mitophagy was not induced. After 24 h of CCCP treatment, all cells retained their 
mitochondrial staining as assessed by immunostaining for the mitochondrial outer membrane 
protein TOM20. These results suggest that PINK1 is not only necessary for the recruitment 
of parkin to dysfunctional mitochondria, but might have other functions apart from parkin 
recruitment in the mitophagy process. 
 
 
 
Figure 35: Mitoparkin is not sufficient to induce mitophagy in PINK1-deficient fibroblasts. PINK1 KO MEFs 
were lentivirally transduced to stably express mitoparkin. The cells were left untreated or 20 μM of CCCP were 
added for 24 h to depolarize mitochondrial membrane potential. Cells were stained with antibodies for mitoparkin 
(PRK8; green) and mitochondria (TOM20; red) and analyzed via indirect immunofluorescence. 
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3.2 Pathogenic parkin species are degraded via the proteasome in 
a p62-dependent manner 
Lewy bodies (LB), cytoplasmic proteinaceous inclusions, are a characteristic hallmark of PD. 
Mutations in the parkin gene cause familiar autosomal-recessive PD with early-onset.  
Interestingly, parkin has been identified as a component of LBs (Schlossmacher et al., 2002), 
and in vitro experiments suggest that some mutations in the parkin coding sequence induce 
parkin misfolding and aggregation. However, it is not clear if and how parkin aggregates can 
be removed from the cell. 
3.2.1 Pathogenic parkin mutants are prone to misfolding and form cytosolic 
aggregates
Wildtype parkin typically displays a homogenous, mainly cytosolic, cellular distribution. In 
contrast, it has been described that pathogenic parkin mutants are prone to misfolding and 
aggregate formation (Winklhofer et al., 2003). In line with this notion, several parkin mutants 
also display distinct biochemical properties such as reduced solubility in ionic and non-ionic 
detergents and differential sedimentation properties during centrifugation (Winklhofer et al., 
2003, Schlehe et al., 2008). However, it is not clear how aggregated parkin protein is 
degraded. To determine how misfolded parkin is removed from cells, mutants were chosen 
that are particularly prone to misfolding: two point mutants with a single amino acid exchange 
(C212Y and C289G) and two truncated parkin mutants, E309X and W453X (Depicted in 
Figure 36). The later mutant is specifically interesting as it reflects a deletion of only 13 
C-terminal amino acids without affecting the C-terminal RING domain of the parkin protein 
which is essential for its E3 ligase activity.  
 
 
 
Figure 36: Modular structure of parkin protein and position of pathogenic mutations. The individual 
domains are colored. Numbers below designate amino acid positions of the respective domain. UBL: 
ubiquitin-like, RING: really interesting new genes, IBR: in-between RING. 
 
HeLa cells were chosen for the analysis of parkin aggregate formation. HeLa cells do not 
express parkin protein, thus effects of endogenous wildtype parkin can be excluded. When 
transiently expressed in HeLa cells, wildtype parkin showed a clear homogenous distribution 
in the cytosol. In contrast, expression of pathogenic parkin mutants resulted in marked 
spotted staining due to cytosolic aggregate formation (Figure 37). Indeed, expression of 
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human wildtype parkin in HeLa cells never resulted in parkin aggregate formation as 
determined by single cell analysis via indirect immunofluorescence. In contrast, all 
pathogenic parkin mutants analyzed exhibited aggregate formation in a subset of cells 
(Figure 37). Moreover, when HeLa cells were transfected with the indicated parkin mutants 
and analyzed for detergent-solubility, all parkin mutants were partially found in the 
detergent-insoluble fraction while wildtype parkin was exclusively present in the soluble 
fraction (Figure 38). 
 
 
 
Figure 37: Pathogenic parkin mutants form cytosolic aggregates. HeLa cells were transiently transfected 
with the indicated parkin species. Upper pictures: Representative immunofluorescence pictures stained with the 
parkin-specific antibody PRK8.  Lower left: Western blot analysis of parkin mutants to determine equal expression 
levels of the mutants (PRK8 antibody). Lower right: Single cell analysis was performed to determine the 
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percentage of parkin-expressing cells with parkin aggregate formation. At least 300 cells were counted in three 
independent experiments and the percentage of cells with parkin aggregate formation was calculated. 
 
 
Figure 38: Pathogenic parkin mutants show reduced solubility in detergents. HeLa cells were transiently 
transfected with the indicated parkin species. Cells were lysed in 0.5 % Triton X-100 and 0.5 % desoxycholic acid 
(v/v) in PBS and separated into detergent-soluble (S) and –insoluble (P) fraction. Equal volumes of S and P 
fraction were subjected to immunoblot analysis using the parkin-specific antibody PRK8. 
 
3.2.2 P62 colocalizes with mutant parkin aggregates 
As a consequence of their large size, protein aggregates are often subject to 
autophagosomal degradation. P62 has been described as an adapter protein that mediates 
the interaction of protein aggregates and autophagosomes, resulting in the clearance of the 
aggregates through the lysosomal pathway. In agreement with this idea, p62 is found in 
close proximity to a number of proteinaceous deposits in different proteinopathies, such as 
Alzheimer’s disease or Amyotrophic Lateral Sclerosis (ALS). Lewy bodies, the protein 
aggregates in PD, are composed of different proteins, and parkin has been identified as a 
constituent of the pathogenic inclusions. To experimentally address the question if p62 is 
found at aggregates of mutant parkin, an immunofluorescence experiment to detect parkin 
and p62 was performed in HeLa cells. The cells were transiently transfected with human 
wildtype parkin or the respective pathogenic mutants. Indeed, endogenous p62 was found to 
colocalize with the majority of parkin aggregates (Figure 39). In cells transfected with empty 
vector only, p62 showed a typical expression pattern with cytosolic staining, vesicular 
staining (resembling autophagosomes) and occasionally nuclear staining. The subcellular 
distribution or abundance of p62 did not change in the presence of wildtype parkin. 
Remarkably, when aggregates of pathogenic parkin mutants were present in the cell, p62 
was sequestered to these cytoplasmic aggregates and displayed colocalization with parkin 
while the rest of the cell was frequently completely devoid of p62 staining (Figure 39). 
To verify the findings obtained in HeLa cells in other cell types, the neuroblastoma cell line 
SH-SY5Y was analyzed. The cells were transiently transfected with pcDNA empty control 
vector, wildtype parkin or selected pathogenic parkin mutants. The analysis included 
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determination of 1) the percentage of cells with parkin aggregates, 2) the percentage of 
cellular parkin aggregates colocalizing with endogenous p62 and 3) the solubility of parkin 
mutants via the detergent-solubility assay (Figure 40 and Figure 41). The analysis of 
SH-SY5Y cells yielded results comparable to the HeLa cells, suggesting that p62 colocalizes 
with misfolded parkin independently of the cell type. 
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Figure 39: Pathogenic parkin mutants colocalize with endogenous p62. Upper panels (previous page): HeLa 
cells were transfected with pcDNA control vector, wildtype parkin or the indicated parkin mutants. Cells were 
stained with PRK8 parkin-specific antibody and p62 polyclonal antibody to stain endogenous p62. In the merge 
channel parkin is depicted in red and p62 in green. Lower panel: quantification of cells with endogenous p62 
colocalizing with parkin aggregates. 
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Figure 40: Pathogenic parkin mutants form cytosolic aggregates in SH-SY5Y cells and colocalize with 
p62. SH-SY5Y neuroblastoma cells were transiently transfected with pcDNA empty control vector, wildtype parkin 
or the indicated parkin mutants. Cells were stained with PRK8 parkin-specific antibody (red) and p62 polyclonal 
antibody (green) to stain endogenous p62. 
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Figure 41: Pathogenic parkin mutants form aggregates in SH-SY5Y neuroblastoma cells and colocalize 
with p62. SH-SY5Y cells were transiently transfected with the indicated parkin mutants. The percentage of cells 
with parkin aggregates and the percentage of cells containing aggregates colocalizing with endogenous p62 
staining was determined. Lower panel: solubility of parkin mutants in Triton X-100 and desoxycholic acid (0.5 % 
(v/v) each in PBS). 
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3.2.3 P62 levels influence the abundance of parkin aggregates 
P62 has been found to colocalize with the majority of mutant parkin aggregates. In order to 
determine a possible influence of p62 on parkin aggregate formation, fibroblasts from 
wildtype and p62-deficient mice were used. Consistent with the results obtained in the 
human cell lines HeLa and SH-SY5Y, wildtype parkin was completely cytosolic and 
homogenously distributed when overexpressed in fibroblasts derived from p62 knockout 
(KO) animals or wildtype littermates. Contrarily, parkin mutants formed cytosolic aggregates 
in wildtype and p62 KO mouse embryonic fibroblasts (MEFs), which is in line with the 
previous findings. Exemplarily, the aggregation of the pathogenic parkin mutant W453X was 
assessed. The parkin stop mutant W453X exhibited spotted aggregates in a subset of cells 
in both wildtype and p62-deficient MEFs (Figure 42). Surprisingly, aggregates were present 
in a significantly higher percentage of parkin expressing p62-deficient cells. While only about 
30 % of cells positive for parkin showed aggregate-like spots within the cytoplasm of wildtype 
MEFs, more than 50 % of cells lacking p62 presented cellular W453X parkin aggregates 
(Figure 43). Similar results were obtained with the parkin mutants C212Y, C289G and E309X 
(Figure 44). The expression of all of these parkin mutants resulted in enhanced aggregate 
formation in the absence of p62. To determine if the increase in parkin aggregates was due 
to the deficiency in p62, p62 was introduced into W453X parkin-expressing cells by transient 
transfection. Indeed, overexpression of wildtype human p62 in the KO MEFs significantly 
reduced the number of cells containing mutant parkin aggregates (Figure 42). Notably, 
overexpression of p62 also reduced the number of aggregates in wildtype MEFs. In contrast, 
expression and cytoplasmic distribution of wildtype parkin was not affected by different levels 
of p62. The data thus show that loss of p62 results in enhanced formation of parkin 
aggregates while p62 overexpression reduces the number of mutant parkin aggregates. 
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Figure 42: The parkin mutant W453X forms aggregates in wildtype and p62-deficient fibroblasts. Wildtype 
and p62 KO MEFs were transiently transfected with the parkin mutant W453X and stained for p62 (polyclonal p62 
antibody; green) and parkin (PRK8; red channel). In the last panel, cells were cotransfected with human wildtype 
p62. Note that overexpression of p62 reduces parkin aggregate formation.
 
 
 
Figure 43: Aggregates of W453X mutant parkin are more abundant in fibroblasts from p62-deficient mice. 
Wildtype and p62 KO MEFs were transiently transfected with the parkin mutant W453X and stained for p62 
(polyclonal p62 antibody) and parkin (PRK8). Left: in p62 KO MEFs, the abundance of parkin-expressing cells 
containing aggregates is significantly higher. Right: coexpression of p62 reduces parkin aggregate formation both 
in wildtype and p62 KO cells. Lower right: representative Western blot analysis (p62 polyclonal antibody) showing 
p62 expression levels for the individual conditions. Thanks to Veronika Hampl for experimental help.
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Figure 44: Aggregates of parkin mutants are more abundant in p62-deficient cells. Wildtype and p62 KO 
MEFs were transfected with wildtype parkin as a control or the indicated parkin mutants. Cells were analyzed for 
the percentage of transfected cells containing parkin aggregates via single cell analysis in indirect 
immunofluorescence experiments. A minimum of 500 cells per condition was assessed in three independent 
experiments.  
 
3.2.4 Proteasomal inhibition enhances mutant parkin aggregate formation 
The previous experimental data provided support for the notion that p62 was involved in the 
degradation of pathogenic parkin mutant aggregates. In order to determine if the ubiquitin-
proteasomal system (UPS) or the autophagy pathway was used for removal of parkin 
aggregates, chemical inhibitors were used. HeLa cells were transiently transfected to 
express the parkin mutant W453X, and then treated with the proteasomal inhibitor 
epoxomycin or the lysosomal inhibitor bafilomycin A1 for 10 h. Treatment of cells with 
epoxomycin significantly increased the number of cells with parkin aggregates (Figure 45). In 
contrast, when cells were incubated with bafilomycin A1, no rise in the number of cells with 
parkin aggregates was observed. Bafilomycin A1 is a specific inhibitor of vacuolar proton 
ATPases, resulting in inhibition of fusion of autophagosomes with lysosomes. Of note, none 
of the chemical inhibitors induced the formation of aggregates of wildtype parkin under these 
conditions. Moreover, similar results were also obtained for the missense mutants C212Y 
and C289G and the truncated E309X mutant of parkin. The effect of enhanced parkin 
aggregate formation on proteasomal inhibition was not specific for HeLa cells but observed in 
other cell lines such as the dopaminergic neuroblastoma cell line SH-SY5Y and embryonic 
fibroblasts derived from wildtype mice (Figure 46). In contrast, when fibroblasts deficient for 
p62 were treated with proteasomal or lysosomal inhibitors, no significant change in the 
number of cells with parkin aggregates was found (Figure 46). Of note, reintroduction of 
exogenous human p62 was able to reduce formation of mutant parkin aggregates both in 
wildtype and p62-deficient fibroblasts. Interestingly, the reduced aggregate formation was 
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completely prevented when proteasomal function was blocked, suggesting that p62 is able to 
target aggregated mutant parkin for proteasomal degradation.  
 
 
 
Figure 45: Proteasomal inhibition enhances parkin W453X aggregate formation in HeLa cells. HeLa cells 
were transiently transfected with the pathogenic parkin mutant W453X. Expression of this mutant in HeLa cells 
resulted in parkin aggregate formation in a subset of cells as assessed by indirect immunofluorescence. 
Pretreatment of cells with the lysosomal inhibitor bafilomycin A1 (30 nM; 10 h) did not change the percentage of 
cells with parkin aggregates. Epoxomycin treatment (100 nM; 10 h) significantly elevated parkin aggregate 
formation.  
 
 
 
Figure 46: Expression levels of p62 and proteasomal inhibition both influence parkin aggregate formation. 
Wildtype and p62 KO MEFs were transfected with parkin W453X. For rescue experiments wildtype human p62 
was cotransfected. Cells were treated with 30 nM of bafilomycin A1 or 100 nM of epoxomycin for 10 h and 
subjected to single cell analysis to determine the percentage of parkin aggregate formation. 
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3.2.5 The autophagosomal-lysosomal pathway is dispensable for degradation 
of mutant parkin aggregates 
Proteasomal, but not lysosomal inhibition by chemical agents resulted in an increase of cells 
with parkin aggregates. The results suggested that autophagy was dispensable for the 
degradation of mutant parkin aggregates. To investigate the role of autophagy in parkin 
aggregate degradation in more detail, fibroblasts from ATG5 KO mice were used. Fibroblasts 
from these mice are deficient for autophagy protein 5 (ATG5), an essential component of the 
core autophagic machinery crucial for autophagosome formation. MEFs from ATG5 KO 
animals are thus defective in accomplishing autophagy (Kuma et al., 2004, Hara et al., 
2006). The percentage of transfected cells with W453X parkin aggregates under basal 
conditions as well as upon blockage of the proteasome or lysosomes with epoxomycin or 
bafilomycin A1 was determined. Aggregate formation of the W453X mutant parkin protein in 
cells deficient for ATG5 was comparable to wildtype cells, with epoxomycin significantly 
increasing the number of aggregates in both cell lines (Figure 47). In agreement with all 
previous experiments, aggregates were never observed when wildtype parkin was expressed 
as a control. Further evidence for autophagy being dispensable for degradation of parkin 
aggregates was obtained by the analysis of autophagy markers in immunofluorescence: 
aggregates of mutant parkin did not colocalize with lysosomal markers such as LAMP1 
(Figure 48). By contrast, a robust co-staining of parkin aggregates with polyubiquitin was 
observed. Making use of linkage-specific ubiquitin antibodies, a marked colocalization of 
parkin aggregates and K48-linked polyubiquitin was found. Contrarily, no labeling of the 
aggregates with a K63 polyubiquitin-specific antibody was observed (Figure 48). These 
findings substantiate the idea that parkin aggregates are degraded by the proteasome rather 
than autophagy, as polyubiquitin linked trough the lysine residue K48 is a classical 
recognition signal for proteasomal degradation. Taken together, the results point out that 
functional autophagy is not involved in the removal of mutant parkin aggregates. 
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Figure 47: Proteasomal inhibition enhances aggregate formation of mutant parkin in autophagy-deficient 
cells. Wildtype and ATG5 KO MEFs were transiently transfected with the parkin stop mutant W453X and treated 
with bafilomycin A1 (30 nM; 10 h) or epoxomycin (100 nM; 10 h). The cells were stained with the parkin-specific 
antibody PRK8 and cells containing aggregates were determined by indirect immunofluorescence. The analysis 
was done by counting at least 500 cells per condition in three independent experiments. 
 
 
Figure 48: Aggregated W453X parkin does not colocalize with lysosomes and preferentially colocalizes 
with K48-linked polyubiquitin. HeLa cells were transiently transfected with the parkin mutant W453X and 
stained with the parkin-specific antibody PRK8 (red) and the indicated antibodies (green channel). LAMP1 is a 
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lysosomal transmembrane protein, staining lysosomal vesicles. Polyubiquitin antibodies specific for lysine-48 
(K48) and lysine-63 (K63) polyubiquitin chains were used in the two lower panels. 
3.2.6 A cell culture model to monitor the degradation of pathogenic parkin 
mutants
The results presented so far have revealed the importance of p62 and proteasomal 
degradation in the removal of parkin aggregates. In order to corroborate these findings, 
stable HeLa cell lines were generated to monitor the effect of proteasomal inhibition on 
parkin aggregate formation. Using lentiviral transduction, HeLa cells overexpressing either 
wildtype parkin or the stop mutant W453X were established. Interestingly, steady-state levels 
of wildtype parkin were much higher than the levels of the W453X stop mutant. This 
phenomenon could be due to rapid degradation of the mutant protein. Indeed, previous 
results from our group suggest that instant degradation of some parkin mutants that cannot 
adopt a native conformation precedes aggregation (Schlehe et al., 2008). Remarkably, 
wildtype parkin is quite stable when overexpressed in cells and the steady-state levels of the 
protein cannot be substantially increased with proteasomal or lysosomal inhibitors. In 
contrast, when cells stably expressing the parkin W453X mutant were treated with 
epoxomycin, there was a significant increase in parkin protein levels (Figure 49). Bafilomycin 
A1 instead did not alter the levels of W453X parkin. Indirect immunofluorescence was 
additionally used to monitor mutant parkin aggregation on single cell level. Consistent with 
the observations from immunoblot experiments, there was only weak W453X parkin signal 
and thus hardly any parkin aggregates detectable under basal conditions (Figure 50). 
However, when cells had been treated with a proteasomal inhibitor prior to analysis, there 
was an increase in parkin staining intensity and a significant rise in the number of cells with 
parkin aggregates. Cells that displayed parkin aggregation showed a marked colocalization 
of p62 with the aggregated parkin protein (Figure 50). Consistent with the previous findings 
these results show that parkin is rapidly degraded in HeLa cells stably expressing low levels 
of the parkin mutant W453X. However, when proteasomal function is impaired, the mutant 
accumulates and forms p62-positive aggregates reminiscent of the experiments with 
transient transfection of parkin mutants (see Figure 42, Figure 40 and Figure 50). 
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Figure 49: Proteasomal inhibition enhances parkin aggregate formation in a stable cell culture model of 
mutant parkin expression. HeLa cells were lentivirally transduced to express the parkin mutant W453X. Left: 
Western blot analysis of parkin levels in these cells following treatment with bafilomycin A1 (30 nM, 10 h) or 
epoxomycin (100 nM, 10 h). 20 μg of protein were separated by SDS-PAGE and immunoblotted with the 
parkin-specific antibody PRK8. GAPDH levels were assessed to determine equal loading. The relative levels of 
parkin to GAPDH were calculated from three independent experiments (upper left panel). Right: analysis of parkin 
aggregate formation in HeLa cells stably expressing parkin W453X via single cell analysis by indirect 
immunofluorescence (treatment with bafilomycin A1 (30 nM, 10 h) or epoxomycin (100 nM, 10 h)). 
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Figure 50: p62 colocalizes with parkin aggregates in stable parkin W453X HeLa cells upon proteasomal 
inhibition. HeLa cells stably overexpressing the parkin mutant W453X were treated with bafilomycin A1 (30 nM) 
or epoxomycin (100 nM) for 10 h. Cells were stained with the parkin-specific antibody PRK8 (red channel) and 
endogenous p62 (p62 polyclonal antibody; green). Parkin aggregates appear upon proteasomal inhibition, and a 
widespread colocalization with p62 can be observed. Note that p62-positive vesicles accumulate both through 
proteasomal and lysosomal inhibition. 
 
In a next step an RNAi approach was used to examine the effect of p62 on degradation of 
mutant parkin protein in a human-derived cell line. The previous results obtained with 
fibroblasts from p62 KO mice pointed towards an essential role of p62 in proteasomal 
degradation of pathogenic parkin aggregates. Small interfering RNA (siRNA) duplexes 
targeting p62 were used to downregulate steady-state levels of p62 and monitor the effect on 
parkin degradation. Cells were transfected with a pool of scrambled control siRNA or siRNA 
specifically targeting p62 and analyzed 24 h after transfection. Transient knockdown of p62 
in HeLa cells stably expressing the parkin mutant W453X indeed increased the levels of 
parkin protein (Figure 51). However, the effect of p62 knockdown was not as prominent as 
observed with proteasomal inhibition by epoxomycin was applied. This might be due to the 
fact that the knockdown was incomplete (5 to 20 % of residual p62 protein present) as 
assessed by Western blot analysis (Figure 51). 
In conclusion, the experimental data obtained from the stable W453X HeLa cells support the 
idea that in contrast to wildtype parkin, the parkin stop mutant W453X is degraded by the 
proteasome in a p62-dependent manner. 
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Figure 51: The parkin mutant W453X accumulates upon siRNA-mediated knockdown of p62. HeLa cells 
stably expressing the parkin mutant W453X were transfected with control (co siRNA) or p62-specific siRNA, 
respectively. Where indicated, cells were additionally treated with 30 nM of bafilomycin A1 or 100 nM of 
epoxomycin 10 h prior to analysis. 24 h after siRNA transfection, cells were harvested and equal amounts of total 
protein (20 μg for parkin and 5 μg for p62 and GAPDH immunoblots) were subjected to Western blot analysis. 
Upper panel: representative immunoblot showing parkin W453X levels in control and p62 siRNA conditions. 
GAPDH was used as a loading control. Lower left graph: quantification of p62 knockdown efficiency from five 
independent experiments. Lower right: quantification of parkin W453X protein levels relative to the housekeeping 
gene GAPDH, based on five independent experiments. 
 
3.2.7 Analysis of mutant parkin W453X in a transgenic mouse model of parkin 
aggregation
The previous experiments on the removal of mutant parkin in different cellular models 
suggested that parkin aggregates are indeed proteasomally degraded in a p62-dependent 
manner. To extend our knowledge about degradation of mutant parkin in an in vivo model, 
we chose to analyze primary cortical neurons from a transgenic mouse model. The 
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transgenic mouse model was established in our group and overexpresses the parkin stop 
mutant W453X under control of the prion promoter, resulting in expression of the parkin 
transgene ubiquitously in the brain. The mouse line was generated, established and 
maintained by other members of our research group (Margit Miesbauer, Angelika Rambold, 
Anita Schlierf and Maria Funke). Primary cortical neurons were prepared from these mice 
and analyzed for parkin expression and solubility under basal conditions and following 
treatment with the proteasomal inhibitor epoxomycin. Spotted aggregates of parkin protein 
were found in a subset of neurons using indirect immunofluorescence (Figure 52). 
Interestingly, p62 staining was found to colocalize with these parkin aggregates. Consistent 
with the results from the cell lines analyzed previously, the mutant parkin protein was almost 
exclusively present in the pellet fraction when the detergent-solubility assay was applied 
(Figure 53). In addition, epoxomycin treatment substantially increased the level of mutant 
parkin protein. Thus, there is additional evidence from primary mouse neurons that mutant 
parkin aggregates can be found in the brain of these mice in vivo and that they are degraded 
by the proteasome. 
 
 
 
Figure 52: Parkin aggregates in primary neurons from W453X parkin-transgenic mice colocalize with p62. 
Primary cortical neurons from parkin W453X-transgenic mouse embryos were stained using the parkin-specific 
antibody PRK8 (red) and the polyclonal p62 antibody (green). Images were acquired using confocal microscopy. 
Thanks to Maria Funke for preparation of the primary neurons and to Kathrin Lutz for help with microscope 
settings and picture acquirement. The arrows in the enlargement point to parkin aggregates that colocalize with 
endogenous p62.  
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Figure 53: Mutant parkin W453X accumulates in primary neurons upon proteasomal inhibition. Primary 
cortical neurons were obtained from parkin W453X-transgenic mouse embryos and wildtype littermates. The 
neurons were exposed to 0.1 μM and 1 μM of epoxomycin for 16 h and analyzed by the detergent-solubility 
assay. Protein samples of neurons from two different parkin-transgenic animals (mouse 1, mouse 2) are shown in 
the representative immunoblot. Thanks to Alexandra Deinlein and Maria Funke for experimental assistance.
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4 Discussion 
4.1 Parkin and mitophagy 
 
Mutations in the parkin gene are responsible for the majority of early-onset Parkinson’s 
disease (PD) cases. Familiar PD caused by parkin mutations is autosomal recessively 
inherited, suggesting that a loss of parkin function could account for the disease. The parkin 
gene encodes an E3 ubiquitin ligase mediating the ubiquitination of substrate proteins.  
Different putative parkin substrates have been identified in vitro, including the parkin-
associated endothelin receptor-like receptor (Pael-R), synphilin-1, glycosylated -synuclein, 
cyclin E, synaptotagmin XI, CASK, the p38/JTV-1 subunit of the multi-tRNA synthetase 
complex, and the parkin-interacting substrate (PARIS) (Zhang et al., 2000, Chung et al., 
2001, Imai et al., 2001, Shimura et al., 2001, Choi et al., 2003, Corti et al., 2003, Huynh et 
al., 2003, Ren et al., 2003, Staropoli et al., 2003, Fallon et al., 2006a, Shin et al., 2011). So 
far, the contribution of these substrates to PD and their disease relevance in vivo remain 
largely speculative. Although parkin displays a broad cytoprotective activity, the exact cellular 
function of parkin has long been veiled. Only recently, the finding that parkin is able to 
mediate the degradation of dysfunctional mitochondria via autophagy has invigorated 
research on the role of parkin and other PD genes on mitochondrial function (Narendra et al., 
2008). Many lines of evidence indicate that mitochondrial dysfunction is a major contributor 
to the development of PD (reviewed in (Schapira and Gegg, 2011, Pilsl and Winklhofer, 
2011). However, it remains to be clarified if mitochondrial dysfunction is a primary cause of 
PD directly eliciting pathogenic events or if it is only a bystander occurring late in disease 
pathogenesis. 
In order to maintain the cellular homeostasis, dysfunctional mitochondria have to be removed 
to prevent damage to the cell and the induction of apoptosis. Mitochondria are remarkably 
dynamic organelles that constantly fuse and divide. When the mitochondrial membrane 
potential is lost, mitochondria undergo a rapid remodeling process, apparent through instant 
fragmentation of the tubular mitochondrial network. Within only a few minutes of cell 
treatment with the protonophore CCCP, the mitochondrial network disintegrates into small, 
spherical single mitochondria. This mitochondrial fragmentation is not specific for CCCP 
treatment but is a general response to many potentially harmful stimuli. In particular, 
mitochondrial fragmentation into smaller organelles is thought to be a prerequisite for 
subsequent degradation in lysosomes, a process called mitophagy (Twig and Shirihai, 2011, 
Twig et al., 2008b, Twig et al., 2008a). Given that HeLa cells do not express endogenous 
parkin, it becomes evident that parkin is not required for the fragmentation of tubular 
mitochondria following the exposure to CCCP. Nevertheless, exogenous parkin readily 
translocates to mitochondria that have lost their membrane potential and initiates their 
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degradation via mitophagy. Parkin-mediated mitophagy is not cell type specific, as it can be 
elicited in many cell types by the combination of parkin overexpression and subsequent 
dissipation of mitochondrial membrane potential. Not only overexpressed parkin, but also 
endogenous parkin can initiate mitophagy, as shown by recent studies in the neuroblastoma 
cell line SH-SY5Y (Van Laar et al., 2011, Lee et al., 2010). The mouse embryonic fibroblasts 
investigated in this thesis do not express endogenous parkin protein, thus, overexpression of 
wildtype parkin via lentiviral transduction was employed. Independently of the cell line 
analyzed herein, mitochondria were never depleted in the absence of parkin, revealing that 
parkin is essential for CCCP-induced mitophagy. The observed slight reduction in 
mitochondrial marker proteins upon prolonged exposure to CCCP in the absence of parkin 
most likely does not reflect degradation via mitophagy but is rather a consequence of 
impaired de novo biosynthesis of mitochondrial proteins or whole mitochondria. Parkin did 
not localize to other cellular compartments such as endoplasmic reticulum (ER) or lysosomes 
upon CCCP treatment, therefore the removal of mitochondria was specific for these 
organelles. In addition, levels of the ER marker protein calnexin and the cytoplasmic enzyme 
GAPDH did not change in response to CCCP or dependent on parkin protein levels, 
suggesting that mitochondria are selectively degraded. 
Previous studies from different groups provided detailed evidence that parkin is a 
cytoprotective protein. It confers an anti-apoptotic effect to cells in various toxic paradigms. 
As an example, parkin is able to protect cells from dopamine-induced apoptosis and from 
excitotoxicity conveyed by kainate (Staropoli et al., 2003, Jiang et al., 2004). In addition, 
parkin displays neuroprotective activity in vivo: we were able to show that human parkin 
reduces the number of TUNEL-positive neurons in the spinal cord of zebrafish upon 
exposure to acute proteotoxic stress induced by heat-shock (Fett et al., 2010). However, the 
connection of parkin-mediated cytoprotection and parkin-dependent mitophagy had not been 
experimentally addressed this far. In principle, it is feasible that parkin exhibits its 
cytoprotective potential through the degradation of dysfunctional mitochondria. Removal of 
mitochondria that have lost their membrane potential could prevent the release of 
pro-apoptotic factors from these defective organelles. As an example, cytochrome c release 
from mitochondria is an important step in apoptosis induction, and a recent study was able to 
show that parkin is capable of preventing the release of cytochrome c (Berger et al., 2009). 
We wanted to address the connection of parkin-induced cytoprotection and mitophagy. To 
examine whether parkin-mediated mitophagy is sufficient to explain the cytoprotective 
capacity of parkin, different cellular toxins were investigated for their potential to induce 
mitophagy. Toxins with differential modes of action were chosen to examine a broad 
spectrum of cellular stress conditions. Chemicals that have a direct impact on mitochondrial 
membrane potential (such as the ionophores CCCP and valinomycin) effectively trigger 
parkin recruitment to dysfunctional mitochondria and initiate mitophagy. Importantly, parkin 
displays anti-apoptotic properties in response to CCCP treatment using identical 
experimental conditions (Bouman et al., 2011). However, cytotoxins that indirectly impair 
mitochondrial membrane potential did not result in a recruitment of parkin to mitochondria: 
the PD-associated toxins 1-methyl-4-phenylpyridinium (MPP+) or paraquat did not trigger 
parkin translocation to mitochondria or mitophagy although they inhibit mitochondrial 
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oxidative phosphorylation and increase the amount of intracellular reactive oxygen species 
(ROS). Previous studies implicated that parkin is cytoprotective in cells exposed to MPP+ or 
paraquat (Wang et al., 2005a), another indication that mitochondrial degradation via 
mitophagy is independent of parkin-mediated cytoprotection. In addition, iron ions did not 
induce mitophagy. Elevated brain iron levels have been described as a risk factor for PD 
development; PD prevalence is higher in people exposed to iron, e.g. among welders and 
farmers (reviewed in (Sian-Hulsmann et al., 2011). Parkin-dependent mitophagy, however, is 
not stimulated by iron ions. Thapsigargin, a selective inhibitor of the SERCA-ATPase, results 
in the elevation of cytosolic calcium levels. Treatment of cells with thapsigargin promotes 
acute mitochondrial hyperelongation as a compensatory cellular stress response. However, 
upon prolonged exposure to ER stress induced by thapsigargin, the mitochondrial network 
fragments. Parkin is both able to prevent thapsigargin-induced mitochondrial fragmentation 
and subsequent cell death (Bouman et al., 2011). Nonetheless, we were able to demonstrate 
that mitochondrial degradation is not triggered by thapsigargin, suggesting independent 
mechanisms of action. In favor of this hypothesis are unpublished findings from our group 
that PINK1 is dispensable for parkin-mediated cytoprotection (Kathrin Lutz, unpublished 
data). In PINK1-deficient mouse embryonic fibroblasts, parkin is able to prevent 
stress-induced apoptosis. In contrast, the findings presented here demonstrate that no 
mitophagy is induced in the absence of parkin. In summary, parkin is a stress-protective 
protein, conferring anti-apoptotic properties to cells exposed to a wide spectrum of toxins. 
Nevertheless, the mechanism of parkin action is not completely understood. The notion that 
mitophagy is not trigged by cellular toxins indirectly affecting the mitochondrial membrane 
potential leads to the conclusion that parkin-mediated mitophagy is not the common 
denominator of parkin cytoprotective activity under various conditions of cellular stress. 
The E3 ubiquitin ligase parkin contains an N-terminal ubiquitin-like (UBL) domain and a 
C-terminal RBR (RING-between RING-RING) domain essential for ligase activity. The 
experimental results presented in this study provide evidence that the UBL domain of parkin 
is dispensable for parkin recruitment to mitochondria and subsequent mitophagy. The UBL 
parkin mutant effectively translocated to mitochondria upon exposure to CCCP and triggered 
degradation of dysfunctional mitochondria to the same extent as wildtype parkin. 
Interestingly, a parkin species lacking the UBL domain is found in vivo, translated from an 
alternative start codon at amino acid 80 (Henn et al., 2005). This smaller parkin protein is 
detected in cell culture and in samples of human brain, assuming a function for this protein in 
humans. In contrast, deletion of any other domain of parkin resulted in partial parkin 
insolubility and cytosolic aggregate formation. These domain deletion mutants all displayed a 
loss-of-function phenotype in mitophagy initiation. Although this implicates an essential role 
of the C-terminal RBR domain and thus a functional E3 ligase activity, no definite conclusion 
can be made from the interpretation of the domain deletion mutant experiments: the parkin 
protein is prone to misfolding and aggregate formation (Henn et al., 2005, Winklhofer et al., 
2003, Hampe et al., 2006, Wang et al., 2005a, LaVoie et al., 2005, LaVoie et al., 2007). Yet 
small modifications of the parkin coding sequence or the addition of an epitope tag can 
interfere with parkin folding and inactivate parkin function. Deletion of whole domains might 
therefore prevent proper parkin folding leading to a dysfunctional protein. In fact, the UBL 
Discussion 
86 
 
parkin is the only deletion mutant that is fully soluble under basal conditions comparable to 
the wildtype protein (unpublished results from our group). 
It has been demonstrated that the E3 ligase activity of parkin is crucial for the cytoprotective 
properties of the protein. Most pathogenic parkin mutants are impaired in the ubiquitination of 
substrates or in autoubiquitination and do not protect cells from apoptosis induced by 
2-mercaptoethanol or tunicamycin (Imai et al., 2000). Besides the importance of the E3 
ubiquitin ligase activity for parkin-mediated cytoprotection, it seems reasonable that the 
function of parkin as an ubiquitin ligase plays a crucial role in mitophagy as well. Following 
translocation of parkin to dysfunctional mitochondria, a robust ubiquitination is found at 
mitochondria. However, the exact substrates of ubiquitination remain to be determined. 
Different hypothetic scenarios are thinkable: 1) Parkin directly ubiquitinates one or several 
mitochondrial substrates at the outer mitochondrial membrane (OMM). This is in line with 
recently published data proposing mitofusin 1 and 2 (Mfn 1/2) as substrates for 
parkin-mediated ubiquitination and degradation (Rakovic et al., 2011, Gegg et al., 2010, 
Gegg and Schapira, 2011, Tanaka et al., 2010, Ziviani et al., 2010, Poole et al., 2010). Data 
of another study further supports this hypothesis. Using the stable isotope labeling by amino 
acids in cell culture (SILAC) technology the authors of this study found a variety of OMM 
proteins ubiquitinated by parkin and degraded following the exposure to CCCP (Chan et al., 
2011). 2) Parkin function might also indirectly influence mitochondrial ubiquitination. It is 
possible that parkin ubiquitinates a specific, so far unidentified, substrate which in turn 
triggers a signaling cascade resulting in mitochondrial ubiquitination. 3) In vitro studies 
demonstrated that parkin reveals autoubiquitination activity (Imai et al., 2000, Zhang et al., 
2000, Tanaka et al., 2010, Shimura et al., 2000). Conceivably, parkin autoubiquitination 
represents a degradation signal which in turn recruits the mitophagic machinery to 
mitochondria. 4) In addition, it is feasible that parkin might be ubiquitinated by another 
ubiquitin ligase. Ubiquitination of parkin might change functional properties of the parkin 
protein, resulting in parkin translocation to mitochondria. 
Results from the analysis of pathogenic parkin mutants provide further evidence for the 
importance of parkin E3 ligase activity in mitophagy. During this study it was observed that 
point mutations in the UBL domain did not affect the mitophagic activity of parkin. However, 
this can be a result of the presence of a smaller parkin species lacking the UBL which is fully 
capable of mitophagy initiation (see 3.1.5). Different studies have yielded contradictory 
results on the capability of parkin UBL mutants on mitophagy: our findings are consistent with 
reports from Geisler and coworkers demonstrating that the two pathogenic point mutants of 
parkin, P37L and R42P, are fully functional in initiating mitophagy (Geisler et al., 2010a). In 
contrast, the R42P mutant was found to partially impair the mitophagic activity of parkin in 
two different recent studies (Lee et al., 2010, Matsuda et al., 2010). Thus, more elaborate 
examinations need to unravel the role of the UBL domain in mitophagy. A possibly interesting 
clue may be derived from a recent in vitro analysis of the parkin UBL domain. The 
experimental data from this group suggest that the UBL domain of parkin functions to inhibit 
its autoubiquitination. Moreover, pathogenic parkin mutations within the UBL disrupt this 
autoinhibition, resulting in a constitutively active molecule (Chaugule et al., 2011). In contrast 
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to the UBL parkin mutants that were functional in our mitophagy assay, several point mutants 
present in the RBR domain severely compromised parkin function. The pathogenic mutant 
G430D (point mutation in the RING 2 domain of parkin) was soluble under basal conditions 
similar to the wildtype protein but did not colocalize with mitochondria upon depolarization of 
the mitochondrial membrane potential. This suggests that the mutant protein is impaired in 
mitochondrial recruitment. Other pathogenic parkin mutants analyzed displayed cytosolic 
aggregate formation and lost the ability to translocate to mitochondria as a consequence. In 
vitro studies demonstrated that most pathogenic parkin mutants are impaired in E3 ubiquitin 
ligase activity (Shimura et al., 2000, Matsuda et al., 2006), which can be an alternative 
explanation for loss of mitophagic activity. Interestingly, the analysis of the pathogenic parkin 
mutant W453X revealed that this mutant is defective in mitochondrial recruitment upon 
CCCP treatment. The W453X mutant lacks only 13 C-terminal amino acids without affecting 
the integrity of the RBR domain. It has been demonstrated that the E3 ligase activity of this 
mutant is impaired in an in vitro assay using a recombinant maltose-binding protein (MBP) 
fused to parkin as a pseudosubstrate (Matsuda et al., 2006). 
The ubiquitination pattern at dysfunctional mitochondria mediated by parkin is characterized 
by both K48- and K63-linked polyubiquitin chains. Linkage of polyubiquitin moieties through 
the lysine residue K48 is a typical trigger for proteasomal degradation. K63-linked 
polyubiquitin chains have been implicated in various cellular signaling processes and in 
particular selective autophagy such as mitophagy. The findings are in accordance with the 
notion that both proteasomal and lysosomal inhibition impair mitophagy but do not affect 
parkin translocation to mitochondria. The results indicate that the two cellular degradation 
systems ubiquitin-proteasomal system (UPS) and autophagy are crucial for successful 
completion of mitophagy. Recently, other research groups have published their experimental 
data on the pattern of parkin-mediated ubiquitination in mitophagy: a study by Geisler and 
coworkers indicates that voltage-dependent anion channel 1 (VDAC1) is tagged by K27- and 
K63-linked polyubiquitin via parkin (Geisler et al., 2010a), although the relevance of VDAC1 
ubiquitination for mitophagy is controversially discussed (Narendra et al., 2010a, Chan et al., 
2011). Investigation of parkin-mediated ubiquitination via the SILAC technology unraveled 
the presence of K48-linked polyubiquitin chains (Chan et al., 2011). However, a lot of debate 
is still ongoing concerning the substrate/s of parkin and the pattern of ubiquitination. 
Nonetheless profound evidence shows that both UPS and autophagy are involved in 
mitophagy. As an example, the group of Richard Youle presents evidence for an involvement 
of p97 and the proteasome in mitophagy (Tanaka et al., 2010). The AAA+ ATPase p97 is a 
cytosolic chaperone that has been found to translocate to dysfunctional mitochondria in the 
presence of parkin. P97 is thought to chaperone OMM proteins for proteasomal degradation. 
Additional evidence for UPS function in mitophagy was obtained by the notion that the 
ubiquitin mutant K48R, which is defective in the assembly of K48-linked polyubiquitin chains, 
impairs parkin-dependent mitophagy (Chan et al., 2011). 
One very interesting observation results from the analysis of ATG5 KO MEFs, which are 
incapable of macroautophagy (see section 3.1.7). ATG5 is an essential component of the 
autophagic machinery (Kuma et al., 2004). When ATG5-deficient cells were tested for the 
Discussion 
88 
 
ability to degrade the OMM protein TOM20 in response to CCCP, no difference was 
observed compared to wildtype control cells, suggesting that autophagy is dispensable for 
mitochondrial degradation. However, when the mitochondrial matrix protein HSP60 was 
analyzed instead, no degradation of this protein was observed in cells lacking ATG5. In line 
with the observation that both proteasomal function and autophagy are required for 
mitochondrial degradation the findings indicate a differential degradation mechanism of OMM 
and matrix proteins. In addition, the proteasomal degradation of OMM proteins seems to be 
independent and upstream of lysosomal degradation. 
The current experimental data support the following working model: Upon dissipation of the 
mitochondrial membrane potential, parkin is recruited to dysfunctional mitochondria. Parkin 
subsequently either directly or indirectly ubiquitinates and induces the proteasomal 
degradation of OMM proteins. This remodeling of the OMM surface is then supposed to be a 
trigger for the subsequent engulfment of the mitochondria into autophagosomes and 
degradation in lysosomes, although these steps are not completely understood. So how is 
parkin recruited to impaired mitochondria? The analysis of PINK1-deficient mouse fibroblasts 
established PINK1 as a key player in parkin-mediated mitophagy (see section 3.1.8). Indeed, 
several groups agree with the idea that PINK1 is responsible for recruitment of parkin to 
mitochondria (Geisler et al., 2010a, Geisler et al., 2010b, Jin et al., 2010, Kawajiri et al., 
2010, Matsuda et al., 2010, Narendra et al., 2010b, Vives-Bauza et al., 2010, Kim et al., 
2008). PINK1 is readily cleaved and degraded under basal conditions. However, when 
mitochondrial membrane potential is lost, PINK1 accumulates at dysfunctional mitochondria 
which in turn triggers parkin translocation. Although it is common sense that PINK1 is 
responsible for parkin recruitment to mitochondria, the exact mechanism still remains elusive. 
Some evidence points towards a potential direct interaction of parkin and PINK1 (Shiba et 
al., 2009); additional in vitro data suggest that the two proteins may also modify each other: 
PINK1 could phosphorylate parkin, or parkin could ubiquitinate PINK1 (Sha et al., 2010, Kim 
et al., 2008, Shiba et al., 2009, Um et al., 2009). PINK1 levels appear to be limiting in 
mitophagy. On the one hand, no mitophagy occurs in PINK1-deficient cells (see section 
3.1.8) and is perturbed upon transient siRNA-mediated knockdown of PINK1 (Geisler et al., 
2010b, Geisler et al., 2010a, Vives-Bauza et al., 2010). On the other hand, overexpression of 
PINK1 is sufficient to induce parkin-mediated mitophagy independent of mitochondrial 
membrane potential (see section 3.1.9). Furthermore, mitochondrial targeting of PINK1 is 
crucial for mitophagy. A PINK1 mutant lacking the C-terminal mitochondrial targeting 
sequence (MTS) did not induce parkin translocation to mitochondria with dissipated 
membrane potential and was deficient in initiating mitophagy (see section 3.1.9 and 
unpublished data from our group). These findings are accordant with the results from 
Narendra and coworkers, demonstrating that an artificial PINK1 mutant anchored to the 
OMM via the MTS and TM domain of Opa-3 induces mitophagy to a greater extent than 
wildtype PINK1 (Narendra et al., 2010b). 
Interestingly, the data obtained in this study suggest parkin folding to be essential for 
mitophagy induction. The parkin protein is soluble under basal conditions. Surprisingly, 
parkin shifted into the detergent-insoluble fraction when cells were treated with the 
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protonophore CCCP. This biochemical alteration of parkin could reflect a structural change of 
the protein accompanied by a functional modification of the protein. Not only CCCP, but also 
PINK1 levels influence parkin solubility: overexpression of PINK1 affects parkin solubility. In 
the absence of PINK1, CCCP can no longer trigger parkin insolubility. Hence, the differential 
solubility of parkin seems to be crucial for mitophagy, although the underlying mechanism is 
unclear. It is possible that parkin adopts a misfolded conformation at mitochondria which in 
turn is a stimulus that tags dysfunctional mitochondria making them accessible for 
subsequent degradation. Additionally, it is feasible that parkin function as an E3 ubiquitin 
ligase is relieved only upon translocation to mitochondria and interaction with PINK1. As an 
example, the interaction of PINK1 could sterically modify parkin in a way that E3 ligase 
activity is triggered. This is in agreement with a recent finding, that parkin might be inactive 
when present in the cytosol and exhibit its E3 ligase activity only upon translocation to 
mitochondria (Matsuda et al., 2010).    
One of the first steps in mitophagy is the recruitment of parkin to dysfunctional mitochondria. 
Our analysis of mitoparkin, an artificial chimeric protein anchoring parkin to the OMM, 
revealed that mitochondrial recruitment of parkin is not sufficient to induce mitophagy (see 
section 3.1.14). Nevertheless, mitoparkin is functional: when mitochondrial membrane 
potential is lost, mitoparkin triggers mitochondrial removal. The functionality of mitoparkin 
was shown in a parkin-deficient background, for instance in HeLa cells that lack endogenous 
parkin. This implicates that another stimulus besides mitochondrial targeting of parkin might 
be necessary to induce mitophagy. Parkin folding is eligible to play a role. Unfortunately, 
mitoparkin folding cannot be assessed following CCCP treatment; mitoparkin is already 
insoluble in detergents under basal conditions. Most likely this is due to the addition of the 
TOM20 TM domain which is highly hydrophobic and might interfere with the solubility of the 
chimeric protein in detergents. Of note, with the detergent conditions used in these 
experiments, endogenous TOM20 protein was partially insoluble as well (own, unpublished 
data). Surprisingly, mitoparkin was not able to induce mitophagy in PINK1-deficient cells, 
neither under basal conditions nor when the mitochondrial membrane potential was 
abolished. These results point towards an alternative role of PINK1 in parkin-dependent 
mitophagy aside from parkin recruitment to mitochondria, the nature of it having to be solved. 
Hypothetically, PINK1 kinase activity could be necessary for activation of parkin E3 ligase 
activity; it has been proposed that PINK1 can mediate phosphorylation of parkin (Kim et al., 
2008, Sha et al., 2010), although other groups do not find supporting evidence for this 
scenario (Vives-Bauza et al., 2010). In addition, recent findings suggest that the E3 ligase 
activity of parkin is only released upon translocation of parkin to mitochondria (Matsuda et 
al., 2010, Lazarou et al., 2012) and this could in principle be mediated through the action of 
PINK1.    
Different pathogenic mutations in parkin or PINK1 interfere with the degradation of 
dysfunctional mitochondria via mitophagy (see section 3.1.4 and (Geisler et al., 2010b, 
Geisler et al., 2010a)). Various pathogenic parkin mutants are prone to misfolding and form 
cytoplasmic aggregates that disable parkin translocation to mitochondria. In addition, E3 
ligase activity is possibly impaired as discussed before. However, treatment of cells with 
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CCCP or overexpression of PINK1 induces alterations in the biochemical properties of 
parkin, leading to parkin insolubility in detergents (see sections 3.1.12 and 3.1.13). In 
addition, pathogenic PINK1 mutants are defective in altering parkin solubility and in inducing 
parkin-mediated mitophagy (see section 3.1.13). Reduced solubility of parkin in detergents 
has been observed previously, although in a different context, and is a biochemical read-out 
for parkin misfolding (see section 3.2.1 and (Winklhofer et al., 2003, Henn et al., 2005, 
Schlehe et al., 2008)). Thus, it could be speculated that a conformational change of parkin at 
mitochondria, possibly even misfolding of parkin, could trigger the removal of dysfunctional 
mitochondria. Nevertheless, the nature of this conformational change has to be addressed in 
more detail. Structural studies on parkin are hampered by the fact that parkin is prone to 
misfolding and could not be crystallized so far. The only available structural data of parkin is 
the three-dimensional folding of the parkin UBL domain which resembles ubiquitin both in its 
primary amino acid sequence (61 % of identical amino acids between ubiquitin and the 
parkin UBL domain) and its three-dimensional structure (Sakata et al., 2003, Tashiro et al., 
2003, Tomoo et al., 2008).  
Mitophagy is commonly quantified in indirect immunofluorescence using parkin 
overexpressing cells that are treated with CCCP and stained for a mitochondrial marker 
protein. This assay however, has certain drawbacks, so the results have to be interpreted 
carefully. First, the uncoupling agent CCCP is a chemical drug inducing an acute and drastic 
depolarization of mitochondrial membrane potential. This situation is quite remote from in 
vivo conditions appearing in PD patients, where a slow and moderate decrease in 
mitochondrial membrane potential may occur over several decades during disease 
development and progression. Besides CCCP, only reagents that directly uncouple 
mitochondrial membrane potential have been successfully tested in the in vitro mitophagy 
assay. Of note, drugs that directly cause a parkinsonian phenotype in rodents, monkeys, and 
humans such as rotenone, paraquat or MPP+, do not induce parkin recruitment or mitophagy 
in cell culture experiments (see section 3.1.3). Second, the majority of studies investigating 
mitophagy rely on single cell analysis of cells stained with the mitochondrial marker protein 
TOM20. The outer mitochondrial membrane (OMM) protein TOM20 has been suggested to 
be degraded via an UPS-dependent mechanism, and might not be a reliable marker to 
analyze downstream autophagy-dependent mechanisms (Chan et al., 2011). The results 
from this study corroborate this idea: mitochondrial staining subsided in ATG5-deficient 
fibroblasts upon CCCP treatment when TOM20 staining was analyzed; contrarily, mitophagy 
was found to be abolished when the mitochondrial matrix protein HSP60 was analyzed 
instead (see section 3.1.7). Another drawback of the mitophagy studies is the use of protein 
overexpression to analyze parkin translocation to mitochondria and subsequent 
mitochondrial degradation. HeLa cells and most established mouse embryonic fibroblast cell 
lines do not express endogenous parkin; the neuroblastoma cell line SH-SY5Y expresses 
parkin, but only at very low levels when undifferentiated. The potential of endogenous parkin 
to induce mitophagy has been demonstrated in SH-SY5Y cells, although the effect is weaker 
and displays a slower kinetic (Lee et al., 2010, Van Humbeeck et al., 2011, Van Laar et al., 
2011). Nevertheless, the use of HeLa cells is especially valuable for the analysis of parkin 
mutants as endogenous wildtype parkin could possibly distort the experimental results (see 
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sections 3.1.4 and 3.1.5). When mitophagy is analyzed in cell culture, pathogenic parkin 
mutants display an impairment of parkin translocation to dysfunctional mitochondria and 
subsequent mitophagy. It will now be important to analyze the impact of these mutations for 
the patients. As an example, fibroblasts from PD patients could be investigated in the context 
of parkin translocation to mitochondria and mitophagy efficiency upon uncoupling of the 
mitochondrial membrane potential. Not only PD patients with mutations in parkin or PINK1 
might be reasonable to examine, but also fibroblasts from sporadic PD patients or patients 
with mutations in other PD genes to see whether parkin-mediated mitophagy is affected. One 
recent study addressed the impact of PINK1 mutations on parkin function and vice versa in 
fibroblasts derived from PD patients (Rakovic et al., 2010). Interestingly, translocation of 
parkin to dysfunctional mitochondria is abrogated in dopaminergic neurons differentiated 
from induced pluripotent stem cells (iPS cells) derived from PD patients carrying PINK1 
mutations (Seibler et al., 2011). 
Although quite a number of studies have investigated the role of parkin in mitophagy, the in 
vivo relevance of the findings is mostly obscure. Neurons have an especially high energy 
demand and rely on functional mitochondria. The initial studies of parkin-mediated mitophagy 
were all conducted in established tumor cell lines, thus it is of special interest to check the 
importance of this pathway for neurons. Tumor cells produce energy mainly through 
glycolysis and do not depend on oxidative phosphorylation. In contrast, ATP generation in 
nerve cells requires efficient energy production through oxidative phosphorylation and 
consequently, a functional mitochondrial network. Furthermore, mitochondrial quality control 
mechanisms are required especially in post-mitotic cells such as neurons (reviewed in 
(Detmer and Chan, 2007)). Therefore, sensing and subsequent degradation of dysfunctional 
mitochondria via the mitophagy pathway would be a feasible mechanism in neuronal quality 
control. Surprisingly, a study in primary rat cortical neurons and mixed striatal/midbrain 
neuronal cultures failed to observe parkin recruitment to mitochondria following CCCP 
treatment (Van Laar et al., 2011). However, in line with other reports, parkin translocation 
was observed when HeLa cells were examined. Notably, mitochondrial recruitment of parkin 
depended on the bioenergetical status of cells – when HeLa cells were forced to produce 
their energy through oxidative phosphorylation instead of glycolysis, parkin translocation to 
mitochondria was completely abolished (Van Laar et al., 2011). Furthermore, Larsson and 
coworkers recently reported on a mouse model enabling to study mitochondrial translocation 
of parkin in vivo (Ekstrand et al., 2007): A conditional knockout of the mitochondrial 
transcriptional factor A (TFAM) in dopaminergic neurons of mice results in mitochondrial 
DNA depletion and severe dysfunction of the respiratory chain (Sterky et al., 2011). 
Dopaminergic neurons in these mice display enlarged, rounded mitochondria in the 
perinuclear region. Nonetheless, parkin did not translocate to these dysfunctional organelles 
in vivo. Besides, additional deletion of parkin in dopaminergic neurons lacking TFAM did not 
exacerbate the observed pathology in these mice. Another study showed that parkin 
mediates protection of dopaminergic neurons in vivo against chronic MPTP toxicity, but does 
not influence Tom20 levels (Yasuda et al., 2011). In addition, exogenous parkin was only 
scarcely located at mitochondria in this mouse model, another indication that the 
cytoprotective function of parkin is probably independent of mitophagy. Thus, the so far 
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obtained results do not support an essential role of parkin-mediated degradation of 
mitochondria in vivo. However, one very recent report suggests that parkin might be able to 
translocate to mitochondria in primary neurons, although the kinetics of parkin recruitment to 
mitochondria is much slower than in tumor cell lines (Cai et al., 2012). In summary, the role 
of parkin-dependent mitophagy for neuronal homeostasis is still heavily debated and requires 
further experimental investigation. Interestingly, parkin is ubiquitously expressed and 
mitochondrial pathology is not restricted to dopaminergic neurons in Drosophila parkin 
mutants (Clark et al., 2006, Greene et al., 2003) and PD patients (reviewed in (Schapira, 
2008, Schapira and Gegg, 2011), suggesting that parkin serves important cellular functions 
outside of the central nervous system. Further research on this topic will be necessary to 
shed light on the impact of the mitophagy pathway in nerve cells and peripheral tissue and 
the role of parkin in this context. 
 
4.2 Degradation of pathogenic parkin mutants 
 
Proteinopathies refer to a class of protein misfolding diseases characterized by abnormal 
protein aggregation in different organs and tissues of the body. Proteinopathies include a 
wide range of diseases such as type 2 diabetes, Alzheimer’s disease and PD. Lewy bodies, 
the intracellular protein aggregates found in PD patients, mainly consist of -synuclein, thus 
PD is categorized as a “synucleinopathy”. Besides -synuclein, a variety of other proteins 
can be found in Lewy Bodies, including ubiquitin, neurofilament, heat-shock proteins, and 
also parkin is found in these intracellular inclusions (Schlossmacher et al., 2002). Protein 
aggregates are a pathological hallmark of various neurodegenerative diseases; aggregates 
of -amyloid (A) and the microtubule-associated protein tau are present in Alzheimer’s 
disease, TAR DNA-binding protein 43 (TDP-43) protein aggregates are found in 
frontotemporal lobar degeneration (FTLD) and amyloidotrophic lateral sclerosis (ALS), 
mutant huntingtin accumulates in Huntington’s disease and conversion of the prion protein 
(PrP) from PrPc to PrPSc causes transmissible spongiform encephalopathies (also known as 
prion diseases). Protein aggregates can confer a toxic gain-of-function, but also induce a 
loss-of-function when proteins essential for cellular functions are sequestered in these 
aggregates. To date, it is not definitely clarified if protein aggregates are beneficial or 
detrimental for cell survival (reviewed in (Winklhofer et al., 2008)). Although the protein 
aggregates in different diseases consist of distinct proteinaceous components, they share 
some common features: extensive ubiquitin staining is often observed at protein inclusions; 
pathological aggregates usually consist of fibers containing misfolded protein with a -sheet 
conformation, termed amyloid; mutations in aggregation-prone proteins can directly cause 
the disease as it is often the case in inherited forms of the different diseases, however 
sporadic forms can occur. In each of these cases, the inclusions are composed of a protein 
that is tightly connected with the cause of the illness. Another common feature of intracellular 
inclusions is the presence of p62 at these protein aggregates. The ubiquitin-binding protein 
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p62 frequently colocalizes with protein aggregates and is used as a marker protein for the 
staining of aggregates in several neurodegenerative diseases (Zatloukal et al., 2002, 
Kuusisto et al., 2008, Kuusisto et al., 2001). For instance, p62 colocalizes with mutant 
huntingtin aggregates in Huntington’s disease (Bjorkoy et al., 2005) and in in vitro and in vivo 
models of expanded polyglutamine huntingtin (Nagaoka et al., 2004). In ALS patients, p62 
immunoreactivity is found at pathological inclusions in anterior horn cells of the spinal cord 
(Mizuno et al., 2006). Multiple system atrophy (MSA) is pathologically characterized by the 
formation of cytoplasmic inclusions in oligodendrocytes containing -synuclein, and p62 
staining can be detected in these inclusions (Chiba et al., 2011). In addition, a robust 
colocalization of p62 and Lewy bodies is observed in the substantia nigra of PD patients 
(Kuusisto et al., 2003). Nevertheless, it remains to be determined what the physiological 
function of p62 at these various protein inclusions is. 
Pathogenic mutations in the parkin gene can result in misfolding of the parkin protein and 
subsequent aggregate formation. Biochemically, protein aggregation can be experimentally 
determined by the formation of aggregates visualized by indirect immunofluorescence or the 
analysis of protein solubility in different detergents such as a combination of ionic or 
non-ionic detergents, urea or sodium dodecylsulfate (SDS). Data from several groups and 
our group determined reduced detergent-solubility and scattered aggregate formation of 
several pathogenic parkin mutants (Winklhofer et al., 2003, Henn et al., 2005, Sriram et al., 
2005, Wang et al., 2005a, Wang et al., 2005b). However, there is limited understanding how 
cells deal with these aggregates and by which mechanism(s) they are degraded. The 
experimental data within this thesis demonstrate the formation of intracellular aggregates of 
mutant parkin while wildtype parkin is homogenously distributed throughout the cytosol (see 
section 3.2.1). However, wildtype parkin is prone to misfolding induced by severe cellular 
stress conditions. Exposure of cells to toxins such as dopamine, MMP+, and peroxide can 
lead to misfolding and aggregate formation of wildtype parkin (Meng et al., 2011, LaVoie et 
al., 2007, LaVoie et al., 2005, Winklhofer et al., 2003, Um et al., 2010, Wong et al., 2007). 
Even proteasomal inhibitors have been found to induce aggregation of wildtype parkin 
(Ardley et al., 2003, Junn et al., 2002, Muqit et al., 2004); however, aggregate formation of 
wildtype parkin was never observed when proteasomal or lysosomal inhibitors were applied 
in the experiments presented in this study. This is probably due to the low concentrations of 
inhibitors used in our experimental setups. The results provided within this thesis do not 
include the analysis of wildtype parkin degradation when parkin misfolding is induced by 
cellular toxins. Although it has been demonstrated that wildtype parkin aggregates upon 
severe cellular stress and is subsequently degraded by autophagy (LaVoie et al., 2005), it 
was not investigated before whether the same pathway is employed for the removal of 
mutant parkin species. Two major cellular degradation systems are feasible to mediate the 
removal of parkin aggregates: the ubiquitin-proteasomal system (UPS) and the 
autophagosomal-lysosomal system (autophagy). The UPS system preferentially degrades 
small and short-lived proteins. In contrast, autophagy is used for the removal of stable 
proteins, whole organelles and various protein aggregates. Due to the large size of protein 
aggregates it was reasonable to speculate that autophagy plays a role in the degradation of 
mutant parkin aggregates. Indeed, when the subcellular localization of the autophagy 
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adaptor protein p62 was analyzed, a robust colocalization of mutant parkin aggregates and 
p62 staining was detected (see section 3.2.2). Using indirect immunofluorescence, p62 was 
often sequestered to the aggregated material, with the rest of the cytoplasm being frequently 
completely devoid of p62 immunoreactivity. 
The p62 protein contains a C-terminal ubiquitin-associated domain (UBA) which enables 
binding to ubiquitinated substrate proteins and an LC3 interacting region (LIR domain) which 
mediates binding to autophagosomes (Pankiv et al., 2007). Although p62 has been used as 
a bona fide marker protein to monitor autophagy, the results obtained in our study provide a 
link to proteasomal degradation of parkin mutants. The experimental evidence provided 
herein points towards a role for the protein in targeting of substrates for proteasomal 
degradation. Although sparse, some findings from other research groups also point towards 
a role of p62 in proteasomal degradation of substrate proteins. For instance, it has been 
proposed that p62 regulates tau levels by targeting the tau protein for proteasomal 
degradation (Babu et al., 2005, Ramesh Babu et al., 2008, Seibenhener et al., 2004). There 
is evidence that p62 can directly bind to the proteasomal subunit Rpt1 (Geetha et al., 2008), 
one of the six ATPases of 19S regulatory particle of the 26S proteasome. It seems 
conceivable that p62 is capable of mediating protein degradation both via the UPS and 
autophagy. Nevertheless, it remains to be demonstrated how the decision between 
proteasomal degradation and autophagy is made in the cellular context. What exactly 
determines whether aggregated proteins are degraded by macroautophagy or whether they 
are subject to proteasomal degradation? Are other proteins involved in decision-making? 
Does it depend on the function of additional factors? One such factor could be neighbor of 
BRCA1 gene 1 (Nbr1), another adapter protein that shares structural homology with p62 and 
has been found to colocalize to Lewy bodies and other pathophysiological aggregates similar 
to p62 (Odagiri et al., 2012). Or do protein modifications such as ubiquitination, 
phosphorylation or sumoylation play a decisive role? All of these questions will have to be 
addressed in the future to provide a better understanding of the mechanism why protein 
aggregates are differentially degraded depending on the protein composition of aggregates, 
the type of disease and the tissue affected. 
Autophagy has been found dispensable for the degradation of mutant parkin aggregates in 
our study (see section 3.2.5). First, inhibition of lysosomal acidification by bafilomycin A1 did 
not affect the amount of cellular aggregates. Second, the abundance of parkin aggregates 
did not differ from wildtype cells when fibroblasts deficient of ATG5 were examined. ATG5 is 
an essential component of the autophagic machinery. However, these results have to be 
interpreted carefully: recently, the identification of a novel autophagy pathway functioning 
independently of ATG5 has promoted the idea that low levels of autophagy can still occur 
even in the absence of ATG5 protein (Nishida et al., 2009). Nevertheless, ATG5-deficient 
cells display major impairments in the execution of general autophagy, and the crucial 
involvement of ATG5 has been demonstrated both in vivo and in cell culture experiments 
(Hara et al., 2006, Kuma et al., 2004). Additional evidence for the notion that autophagy is 
not required for removal of parkin aggregates originates from the analysis of autophagy 
marker proteins in indirect immunofluorescence (see section 3.2.5). No colocalization of 
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parkin aggregates with lysosomal proteins was observed. In addition, aggregates were 
positive for immunoreactivity of K48-linked polyubiquitin, but not K63-linked polyubiquitin, 
suggesting proteasomal degradation rather than removal via autophagy. Nonetheless, a 
collaboration of the UPS and autophagy under certain circumstances is feasible. Reports in 
literature support the idea that substrates degraded by the UPS under normal conditions are 
subjected to lysosomal degradation in case of impaired proteasomal function (reviewed in 
(Zheng et al., 2009)). 
How are misfolded parkin mutants recognized by p62? Two possible scenarios are thinkable: 
First, p62 is able to recognize polyubiquitinated proteins via its UBA domain (Wooten et al., 
2005, Long et al., 2008). Mutant parkin is heavily ubiquitinated (unpublished data from our 
group), thus it is possible that p62 binds polyubiquitin chains that are covalently attached to 
the mutant parkin protein. However, the nature of the linkage of ubiquitin chains at parkin is 
not completely solved. The results from the immunofluorescence experiments suggest that 
lysine K48, but not lysine K63 is exploited for building the polyubiquitin chains found at parkin 
aggregates. In addition, differently conjugated polyubiquitin could also be present, such as 
K27-linked ubiquitin, or possibly monoubiquitination as well. In principle, one ubiquitin moiety 
contains seven lysine residues, all of which can be employed for the assembly of 
polyubiquitin chains. Additionally, only recently linear ubiquitination has been identified as an 
alternative mode of polyubiquitination, linking the N- and the C-termini of ubiquitin residues to 
form a head-to-tail linear polyubiquitin chain (Kirisako et al., 2006). Thus, a plethora of 
putative modes of ubiquitin linkages is hypothetically possible. Besides this, other 
ubiquitinated components aside of parkin might be present in aggregates which could give 
rise to the ubiquitin signal. Furthermore, it is not clear whether p62 can bind all types of 
ubiquitinated proteins with similar affinity or if the linkage pattern of the polyubiquitin chains 
impacts the p62 interaction. Alternatively, p62 could directly interact with parkin through a 
classical UBA/UBL interaction. The UBA domain of p62 is capable of binding to UBL 
domains, such as the UBL domain found in the parkin protein, although the interaction of the 
two proteins still requires experimental proof. The UBL of parkin shares a high sequence 
homology with ubiquitin and structurally resembles ubiquitin, thus it is possible that p62 is 
able to bind parkin directly through the UBL domain. 
The establishment of stable cell lines overexpressing the parkin mutant W453X provided 
additional insights into the degradation of the pathogenic parkin protein. Cells were 
generated by lentiviral transduction, resulting in overexpression of the protein at lower levels 
than achieved by transient liposome-mediated transfection. The parkin mutant W453X was 
rapidly degraded in the stably transduced HeLa cells, resulting in low steady-state levels of 
the pathogenic protein. This observation implies a loss-of-function mechanism of pathology 
rather than a toxic gain-of-function of the mutant protein. The low expression of the mutant 
protein in stable cells might better reflect the situation occurring in PD patients. This is 
supported by the observation that the W453X parkin mutant does not confer toxicity in cell 
culture and in transgenic mice under basal conditions (own observations and unpublished 
results from our group). However, it is possible that in the course of PD, mutations in the 
parkin gene are not sufficient to trigger pathology. PD is a disorder where environmental 
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factors can play a crucial role in disease development. Thus, a detrimental interplay of 
genetic predisposition and environmental toxins might result in the degeneration of neurons 
in the substantia nigra. This is in agreement with experimental data from our group 
demonstrating that the parkin W453X mutant is not toxic to cells under basal conditions but 
exhibits toxicity when proteasomal function is impaired (unpublished results). Of note, a 
reduction of proteasomal activity has been found in patients suffering from PD (reviewed in 
(Cook et al., 2012)). In addition, proteasomal inhibition causes striatal degeneration in 
rodents (Zhu et al., 2007a, Zeng et al., 2006, Sun et al., 2006, McNaught et al., 2002b, 
McNaught et al., 2002a), although some doubts have been raised concerning the selective 
toxicity of proteasomal inhibitors on nigro-striatal neurons (Mathur et al., 2007).  
The abundance of cellular p62 protein affects the quantity of parkin aggregation. Levels of 
mutant parkin can be stabilized both by proteasomal inhibitors or transient downregulation of 
p62 through RNA interference in cells stably expressing W453X parkin (see section 3.2.6). In 
addition, enhanced formation of mutant parkin aggregates in cells deficient for p62 is 
observed. Along with this, overexpression of p62 is able to reduce the percentage of cells 
with parkin aggregates both in fibroblasts derived from p62 knockout mice or wildtype 
littermates (see section 3.2.3). The results point towards an essential role of p62 in the 
degradation of misfolded parkin protein. However, it cannot be ruled out that other factors 
aside of p62 aid in the degradation of parkin mutants. In addition, the in vivo relevance of the 
findings from this study remains to be clarified. Some conclusions can be drawn from the 
analysis of W453X transgenic mice: p62 colocalized with parkin aggregates in ex vivo 
cultures of primary cortical neurons of these transgenic mice. In addition, upon treatment of 
the neurons with a proteasomal inhibitor, protein levels of W453X parkin were elevated, 
suggesting that mutant parkin protein is indeed removed by proteasomal degradation in vivo. 
The results obtained in this study provide a novel link between proteasomal degradation of 
pathogenic parkin mutants and the adapter protein p62. Understanding the mechanism by 
which aggregates of mutant parkin are removed from cells might aid the development of 
strategies to overcome the cellular protein overload and eventually prevent the detrimental 
cascade ultimately provoking neuronal demise. It might furthermore be interesting to 
investigate if p62 is able to mediate the degradation of other aggregation-prone proteins that 
are present in various neurodegenerative diseases. The ultimate goal would be the 
development of therapeutic strategies to halt or even prevent the occurrence of 
proteinopathies. 
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5 Material 
For all experiments, standard laboratory equipment was employed. All chemicals were 
purchased from Merck, Sigma, Roth or Fluka with analytical grade p. A. (pro analysi) if not 
specified differently. 
5.1 Drugs and inhibitors 
 
chemical
(abbreviation)
chemical           
(full name) 
drug target/
application
concentration
 
 
 
   
CCCP carbonyl cyanide 
m-chlorophenyl 
hydrazone 
protonophore 10 – 20 μM 
baf A1 bafilomycin A1 lysosomal H+ATPase 
inhibitor 
30 nM 
epoxo epoxomycin proteasomal inhibitor 10 – 100 nM 
TG thapsigargin inhibitor of SERCA ATPase 10 μM 
valinomycin valinomycin potassium ionophore 2 μM 
oligomycin oligomycin inhibitor of mitochondrial 
ATP synthase 
10 μM 
Fe2+ iron(II) chloride induction of oxidative stress 5 mM 
Fe3+ iron(III) citrate iron toxicity 5 mM 
paraquat N,N-dimethyl-4,4-
bipyridinium 
dichloride 
oxidative stress; production 
of superoxide free radical 
1 mM 
MPP+ 1-methyl-4-
phenylpyridinium 
chloride 
inhibitor of mitochondrial 
respiratory chain complex I 
1 mM 
glutamate glutamic acid excitotoxicity 1 mM 
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5.2 Enzymes 
 
Enzyme Provider 
Restriction enzymes New England BioLabs, Fermentas, Roche 
Applied Science 
Taq DNA polymerase Roche Applied Science 
Pfu DNA polymerase Stratagene 
Pwo DNA polymerase Roche Applied Science 
rapid shrimp alkaline phosphatase (SAP) Roche Applied Science 
T4 DNA ligase Fermentas 
Klenow fragment Fermentas, Thermo Scientific 
 
5.3 Primers and Oligonucleotides 
Primers were synthesized by Thermo Fisher Scientific, HPLC purified and lyophilized. Stock 
solutions of 100 μM (100 pmol/μL) were prepared and stored at -20 °C. 
5.4 Buffers 
Running buffer for SDS-PAGE 
25 mM Tris/HCl, pH 6.8 
190 mM glycine 
0.1 % (w/v) SDS 
 
TBE (running buffer for agarose gel electrophoresis) 
0.9 M Tris base, pH 8.3 
0.9 M boric acid 
20 mM EDTA 
TBS
25 mM Tris/HCl, pH 7.2 
150 mM NaCl 
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TBST 
0.1 % (v/v) Tween-20 in TBS 
PBS 
137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 x 2 H2O 
2 mM KH2PO4 
 
PBS for immunofluorescence 
PBS supplemented with calcium and magnesium (CaCl2 x 2H2O 0.132 g/L; MgCl2 x 6H2O 
0.1 g/L) (PAA Laboratories) 
PBST 
0.1 % (v/v) Tween-20 in PBS 
 
Upper tris buffer for SDS-PAGE 
0.5 M Tris/HCl pH 6.8, 
0.4 % (w/v) SDS 
Lower tris buffer for SDS-PAGE 
1.5 M Tris/HCl, pH 8.8, 
0.4 % (w/v) SDS 
Blotting buffer 
20 mM Tris-Base 
150 mM glycine 
0.01 % (w/v) SDS 
20 % (v/v) methanol 
 
Cell lysis buffer 
0.1 % to 1 % Triton X-100 in PBS 
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Detergent-solubility assay buffer 
0.5 % (v/v) Triton X-100 
0.5 % (w/v) desoxycholic acid 
in PBS 
Laemmli sample buffer (LSB) 
60 mM Tris, pH 6.8 
1 % (w/v) SDS 
10 % (v/v) glycerol 
0.01 % (w/v) bromphenol blue 
1 % 2-mercaptoethanol 
 
Transformation buffer I (for chemically competent bacteria) 
30 mM potassium acetate (CH3CO2K) 
100 mM RbCl 
10 mM CaCl2 
50 mM MnCl2 
15 % (w/v) glycerol 
pH 5.8, sterilized by filtration 
 
Transformation buffer II (for chemically competent bacteria) 
10 mM MOPS (3-(N-morpholino)propanesulfonic acid) 
75 mM CaCl2 
10 mM RbCl 
15 % (w/v) glycerol 
pH 6.5, sterilized by filtration 
 
6x DNA Sample Buffer 
0.25 % (w/v) bromphenol blue 
0.25 % (w/v) xylene cyanol 
30 % (v/v) glycerol 
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5.5 Mammalian cell lines and primary cortical neurons 
 
Name Origin Specification Culture conditions 
HeLa human cervical 
adenosarcoma 
DSMZ # ACC 57 DMEM, 10 % fetal calf 
serum (FCS) 
HEK293T human embryonic kidney DSMZ # ACC 305 DMEM, 10 % fetal calf 
serum (FCS) 
SH-SY5Y human neuroblastoma DSMZ # ACC 209 DMEM GlutaMAX, 
15 % fetal calf serum 
(FCS), non-essential 
amino acids 
MEF mouse embryonic 
fibroblasts 
isolated from 
wildtype, ATG5 KO, 
PINK1 KO, p62 KO 
mice, all 
immortalized 
DMEM, 10 % fetal calf 
serum (FCS) 
primary 
cortical 
neurons 
parkin W453X transgenic 
mice and wildtype 
littermates, E14.5 – E15.5 
provided by Maria 
Funke 
Neurobasal medium, 
B-27 serum-free 
supplement, NGF and 
bFGF (10 ng/mL) 
 
5.6 Cell culture reagents and media 
5.6.1 Reagents and media for mammalian cell culture 
 
Reagent Supplier 
Dulbecco’s Modified Eagle Medium (DMEM) Invitrogen 
DMEM/F12 Invitrogen 
OptiMEM Invitrogen 
fetal calf serum (FCS) Invitrogen 
trypsin solution Invitrogen 
Lipofectamine2000 Invitrogen 
Lipofectamine reagent Invitrogen 
PLUS reagent Invitrogen 
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non-essential amino acids Invitrogen 
RNAiMAX Invitrogen 
siGENOME smart pool Dharmacon 
 
5.6.2 Media for bacteria 
LB liquid medium 
1 % NaCl 
1 % bacto tryptone 
0.5 % yeast extract 
 
LB agar 
1 % NaCl 
1 % bacto tryptone 
0.5 % yeast extract 
1.5 % bacto agar 
5.7 Antibodies 
5.7.1 Primary antibodies 
Antibody Dilution Supplier 
HSP 60 (goat polyclonal) (N-20): sc-1052 1:2.000 Santa Cruz 
Biotechnology 
Ubiquitin FK-1  (total polyubiquitin; mouse 
monoclonal) 
1:500 Biomol 
Ubiquitin Lys63-specific clone Apu3 (rabbit 
monoclonal) 
1:500 Millipore 
Ubiquitin Lys48-specific clone Apu2 (rabbit 
monoclonal) 
1:500 Millipore 
total ubiquitin (N-19): sc-6085 (goat polyclonal) 1:1.000 Santa Cruz 
Biotechnology  
parkin PRK8 (mouse monoclonal) 1:1.000 (IF), 
1:2.000 (WB) 
Santa Cruz 
Biotechnology 
parkin (rabbit polyclonal) #2132 1:500 (IF), 1:1.000 Cell Signaling 
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(WB) Technology 
TOM20 (FL-145): sc-11415 (rabbit polyclonal) 1:2.000 (IF), 
1:5.000 (WB) 
Santa Cruz 
Biotechnology  
TOM20 (mouse monoclonal), #612278 1.2.000 BD Transduction 
Laboratories 
p62/SQSTM1 (rabbit polyclonal) 1:1.000 (IF), 
1:3.000 (WB) 
MBL (Medical & 
Biological 
Laboratories; 
Japan) 
p62/SQSTM1 (mouse monoclonal) 1:1.000 (IF), 
1:5.000 (WB) 
BD Biosciences 
cytochrome c (mouse monoclonal), #556432 1:500 (IF) BD Biosciences 
cytochrome c (mouse monoclonal), #556433 1:500 (WB) BD Biosciences 
LC3 clone 5F10 (mouse monoclonal) 1:500 nanoTools 
active caspase-3 (rabbit polyclonal) 1:1.000 Promega 
GAPDH (mouse monoclonal) 1:10.000 Ambion 
calnexin (rabbit polyclonal) 1:20.000 Thermo Fisher 
Scientific, 
Stressgen 
GFP (mouse monoclonal) 1:1.000 Clonetech 
V5 epitope antibody (mouse monoclonal) 1.1.000 (IF), 
1:2.000 (WB) 
Invitrogen 
LAMP1 H4A3 (mouse monoclonal) 1:2.000 Abcam 
 
5.7.2 Secondary antibodies 
Antibody (all from Invitrogen) Dilution Application 
donkey-anti-mouse (HRP-conjugated) 1:12.000 WB 
donkey-anti-rabbit (HRP-conjugated) 1:12.000 WB 
goat-anti-mouse (ALEXA 488-conjugated) 1:1.000 IF 
goat-anti-mouse (ALEXA 555-conjugated) 1:1.000 IF 
goat-anti-rabbit (ALEXA 488-conjugated) 1:1.000 IF 
goat-anti-rabbit (ALEXA 555-conjugated) 1:1.000 IF 
donkey-anti-goat (ALEXA 546-conjugated) 1:1.000 IF 
Material 
104 
 
 
5.8 Plasmids 
5.8.1 Commercial vectors 
 
Name  Supplier 
pcDNA3.1-Zeo(+)  Invitrogen 
pcDNA3.1-Zeo(-)  Invitrogen 
pcDNA6-V5/HIS-A  Invitrogen 
pEYFP  Clontech 
pCMV-HA  Clontech 
 
5.8.2 Mammalian expression vectors 
 
Expressed cDNA Vector backbone Reference/provider 
human wildtype parkin pcDNA3.1-Zeo(+) Winklhofer et al., 2003 
parkin W453X pcDNA3.1-Zeo(+) Winklhofer et al., 2003 
parkin C212Y pcDNA3.1-Zeo(+) Dr. Lena Bouman 
parkin C289G pcDNA3.1-Zeo(+) Dr. Lena Bouman  
parkin G430D pcDNA3.1-Zeo(+) Dr. Iris Henn  
parkin E409X pcDNA3.1-Zeo(+) Dr. Iris Henn  
parkin UBL pcDNA3.1-Zeo(+) Dr. Iris Henn  
parkin linker, RING1, 
IBR, RING2 
pcDNA3.1-Zeo(+) Dr. Julia Schlehe 
human p62 pcDNA3.1-Zeo(+) Anna Pilsl and Benjamin 
Schwenk 
mitoparkin 
 
mitoGFP (coding sequence 
of parkin replaced by GFP in 
the mitoparkin plasmid) 
pcDNA3.1-Zeo(+) 
 
pcDNA3.1-Zeo(+) 
Anna Pilsl and Veronika 
Hampl 
 
Anna Pilsl 
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PINK1-V5 pcDNA6-V5/HIS-A Dr. Nicole Exner 
PINK178 pcDNA6-V5/HIS-A Dr. Nicole Exner 
PINK1110 pcDNA6-V5/HIS-A Kathrin Lutz 
PINK1 W437X, G309P, 
L347P, Q126P 
pcDNA6-V5/HIS-A Dr. Nicole Exner 
DJ-1-V5 pcDNA6-V5/HIS-A Irrcher et al., 2010 
 
5.8.3 Lentiviral expression vectors 
 
Name of vector Reference/provider 
psPAX2 Addgene #12260, Peer Hendrik Kuhn 
pcDNA3.1 (-)-VSV-G Peer Hendrik Kuhn 
FU-Zeo (empty vector) Peer Hendrik Kuhn 
FU-Zeo-parkin wildtype Peer Hendrik Kuhn and Anna Pilsl 
FU-Zeo-parkin W453X Peer Hendrik Kuhn and Anna Pilsl 
FU-Zeo-GFP Peer Hendrik Kuhn 
 
Methods 
106 
 
6 Methods 
6.1 Nucleic acid techniques 
6.1.1 Polymerase chain reaction 
Polymerase chain reaction (PCR) was performed to specifically amplify DNA, to screen 
bacterial clones for plasmids via colony PCR and to introduce mutations into plasmids. 
Primers used are specified in the material section. Pwo polymerase from Pyrococcus woesei 
was used for cloning applications owing to its proofreading activity.  
PCR reactions were performed in a final volume of 50 μL containing the following 
components: 100 ng of template DNA, 10 pmol each of forward and reverse primer, 2 U of 
Pwo polymerase, and 100 μmol of dNTPs in 1 x PCR reaction buffer. 
The PCR amplification was performed in three subsequent steps: first, the template DNA 
was denatured (94 °C; 20 s), followed by annealing of the primers to the DNA (55 °C to 
72 °C; depending on their melting temperature). In a third step, elongation of the DNA was 
done at 72 ° C for 1 min per kilobase. Generally, 30 cycles of amplification were performed. 
For mutagenesis, primer pairs containing the desired mutation and a flanking region were 
designed. Mutagenesis was either performed using site-directed mutagenesis (Stratagene) 
or a two step PCR approach. 
6.1.2 Restriction digest 
Restriction enzymes were used according to supplier’s instructions. Double digestion was 
performed in 1 x TANGO buffer or NEB buffer 4 if feasible. Typically, 1 U of restriction 
enzyme was used for 1 μg of DNA in a total volume of 20 μL. Restriction digests were 
incubated for at least 1 h.  
6.1.3 Agarose gel electrophoresis 
DNA solutions were mixed with 6 x DNA loading buffer and analyzed via agarose gel 
electrophoresis (0.8 to 2 % agarose in TBE buffer, depending on DNA size analyzed) using 
GeneRuler 1 kbp as a standard. DNA was visualized with ethidium bromide and documented 
under UV light. 
6.1.4 Purification of DNA from agarose and clean-up of PCR reactions 
DNA fragments from agarose gels were excised with a clean scalpel and transferred to a 
fresh plastic tube. Purification of these fragments or clean-up of PCR reactions was 
performed using the NucleoSpin Extract kit (Macherey-Nagel) according to the manual. 
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6.1.5 Dephosphorylation of linearized vectors 
In order to prevent religation of the vector backbone (especially when restriction digests were 
performed with a single enzyme), the terminal phosphates of the open vector were removed 
using rapid shrimp alkaline phosphatase (SAP). A typical dephosphorylation reaction was 
performed in 20 μL of 1 x phosphatase buffer with 2 U of SAP for 1 h at 37 °C. 
6.1.6 Ligation of DNA fragments 
DNA fragments were ligated using T4 DNA ligase. For the insertion of a PCR fragment into a 
vector, the DNA was incubated in a total volume of 20 μL of 1 x ligase buffer. Typically, 
vector and insert were used in a ratio of roughly 1:3. The ligation reaction was incubated at 
room temperature for 2 h or at 16 °C overnight. 
6.1.7 Preparation of competent bacteria 
Chemically competent Escherichia coli (E.coli) DH5 were prepared via the rubidium chloride 
method. 200 mL of LB medium were inoculated with 3 mL of a overnight E.coli culture and 
grown to an optical density of OD600 = 0.6. Cells were chilled on ice for 10 min, afterwards 
centrifuged at 800 g for 10 min at 4 °C. The cell pellet was resuspended in 100 mL of 
transformation buffer I and incubated on ice for 20 min. Following additional centrifugation 
(800 g; 10 min; 4 °C), the cells were resuspended in 10 mL of transformation buffer II and 
chilled on ice for another 60 min. Aliquots of 100 μL were transferred into sterile 1.5 mL 
plastic tubes, immediately frozen in liquid nitrogen and stored at -80 °C until use. 
6.1.8 Transformation of bacteria and screening 
For transformation, the internalization of DNA plasmids by bacteria, one aliquot of chemically 
competent bacteria was thawed on ice for a minimum of 10 min. The ligation mixture was 
added and incubated on ice for additional 10 min. Heat-shock was applied (42 °C, 30 sec), 
followed by chilling of the suspension on ice for 5 min. Afterwards, 0.5 mL of LB medium was 
added to the bacteria and the bacterial suspension was incubated for 30 min at 37 °C with 
agitation. 100 μL of the cell suspension were plated on agar plates containing the appropriate 
selection antibiotic and incubated at 37 °C until single colonies appeared.  
Single bacterial colonies were inoculated into liquid LB medium and allowed to grow 
overnight. Screening for positive clones was either done by purification of DNA and analytical 
digest or by colony PCR screening.  
6.1.9 DNA Sequencing 
DNA sequencing reactions were performed by GATC Biotech using Sanger sequencing on 
the Applied Biosystems 3730xl DNA Analyzer. The obtained sequences were analyzed using 
CLC Main Workbench 6.1 or Vector NTI 10.1.  
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6.1.10 Preparative and analytical scale plasmid DNA preparation 
For isolation and purification of plasmid DNA, E. coli were grown in LB medium (3 mL for 
analytical, 150 mL for preparative extraction) and harvested by centrifugation. DNA was 
isolated using the NucleoSpin Plasmid (Macherey-Nagel) or the Quiagen Midi kit according 
to the provided protocol. DNA concentration and purity were determined by photometric 
measurement using the NanoDrop photospectrometer (PeqLab). 
6.2 Cell culture methods 
6.2.1 Culture and maintenance of mammalian cell lines 
Cell lines were cultured as monolayers in 10 mL of the appropriate medium (see material 
section) in 75 cm2 tissue culture flasks. Cells were maintained at 37 °C in a humified 
atmosphere containing 5 % CO2. 
At regular intervals cells were passaged by trypsinization. For propagation, the cells were 
washed with sterile PBS and 1 mL of trypsin solution was added until the cells detached from 
the surface.  The cells were resuspended in fresh medium and an appropriate amount of cell 
suspension (dilution typically ranging from 1:6 to 1:50) was added to a fresh tissue culture 
flask containing 10 mL of medium.  
For experiments, cells were seeded in 3.5 cm or 2.0 cm cell culture dishes at a confluency of 
30 to 50 %, usually the day before treatment or transfection.  
For cryoconservation and long term storage, the cells were trypsinized and resuspended in 
fresh medium to inactivate the trypsin. Cells were pelleted by centrifugation (1.000 g, 3 min, 
4 °C) and resuspended in medium supplemented with 10 % DMSO. Cell suspensions were 
aliquoted in 2 mL screw cap tubes and placed in an isopropanol cryofreezing container which 
allows freezing of the cells with a cooling rate of 1 °C/min. The tubes were subsequently 
stored in liquid nitrogen. 
6.2.2 Preparation and cultivation of primary cortical neurons 
Murine primary cortical neurons were provided by Maria Funke or Elisa Motori. Cortical 
neurons were cultured from mutant W453X parkin transgenic mouse embryos or 
non-transgenic littermates at E14.5–E15.5 days of gestation and individually processed. 
Cortices were dissected and dissociated with 20 U/mL of papain. Genotypes were 
determined by PCR of peripheral tissue. Neurons from each embryo were plated individually 
into dishes (1.5 million cells/3.5 cm well) coated with poly-D-lysine (100 mg/ml) in 
Neurobasal medium (Invitrogen) supplemented with B-27 serum-free supplement, NGF and 
bFGF (10 ng/mL). At three to four days in vitro, cortical neurons were treated with 0.1 μM or 
1 μM epoxomycin for 16 h and further processed for immunofluorescence or detergent 
solubility assay. 
Methods 
109 
 
6.2.3 Liposome-mediated transient transfection 
Cells were plated 24 h prior to transfection. At 60 to 70 % confluency, cells were transfected 
using Lipofectamine2000 or Lipofectamine PLUS reagents according to manufacturer’s 
instructions. The transfection mix was prepared in OptiMEM and added to the cells for 3 h. 
Thereafter, the medium was replaced by fresh medium and cells were incubated for at least 
20 h prior to drug treatment or cell analysis. 
6.2.4 Establishment of stable cell lines via lentiviral transduction 
Cell lines stably overexpressing wildtype parkin or the pathogenic mutant W453X were 
generated by lentiviral transduction. To this end, the coding sequence of wildtype human 
parkin was subcloned into the Fu-Zeo vector (Kuhn et al., 2010, Lutz et al., 2012) using the 
restriction enzymes BamHI and NotI. An empty control vector and a vector containing the 
coding sequence of green fluorescent protein (Fu-Zeo-GFP) were cloned and provided by 
Peer Hendrik Kuhn. Expression of all constructs is under control of the ubiquitin C promoter. 
Lentiviral particles were generated by transient cotransfection of HEK293T cells with the 
plasmids psPAX2 (0.5 μg), pCDNA3.1 (-)-VSV-G (0.5 μg) and FU-Zeo (0.75 μg), using 
Lipofectamine2000 in OptiMEM. The medium was replaced by fresh DMEM supplemented 
with 10 % FCS one day after transfection. Overnight conditioned medium was filtered 
through 0.45 mm sterile filters and directly added to the target cells. Cells were analyzed for 
transgene expression by immunofluorescence and Western blotting one week after lentiviral 
transduction. 
6.2.5 Transient silencing of target genes using siRNA 
Knockdown of target genes by RNA interference (RNAi) results in a transient and primarily 
gene-specific reduction in gene expression. To this end, 25 nM of small interfering RNA 
(stealth siRNA, Invitrogen or siGENOME SMART pool, Dharmacon) were transiently 
transfected using Lipofectamine RNAiMax. Knockdown efficiency for p62 protein levels was 
determined by immunoblotting of 10 μg of total protein, with GAPDH as a loading control. 
Cells were analyzed 24 h after transfection of the siRNA. 
6.2.6 Cell harvest and lysis 
Monolayers of cells were washed with PBS and detached from the dish surface using a cell 
scraper or 1 mL of trypsin solution. Afterwards, the cells were transferred to plastic tubes and 
pelleted by centrifugation (6.000 g, 5 min, 4 °C). Supernatant was aspired and the cell pellet 
was either lysed directly thereafter or stored at -20 °C until further analysis. 
Whole cell lysated were prepared by direct immersion and homogenizations in Laemmli 
sample buffer containing 10 % (v/v) 2-mercaptoethanol (LSB). Post-nuclear supernatant was 
obtained by lysing cells in an appropriate volume of lysis buffer (typically 0.1 to 1 % Triton 
X-100 in PBS supplemented with complete protease inhibitor cocktail) on ice for 5 min. 
Following centrifugation (13.000 g, 1 min, 4 °C) the supernatant was transferred to a fresh 
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tube and supplemented with LSB. If applicable, total protein concentration was measured 
prior to addition of LSB using the colorimetric bicinchoninic acid assay (BCA). 
6.3 Protein biochemistry 
6.3.1 Measurement of total protein content 
For determination of total protein concentration in cell lysates prior to immunoblot analysis, 
the colorimetric bicinchoninic acid (BCA) method (Pierce) was used according to 
manufacturer’s instructions. Serial dilutions of bovine serum albumin (BSA; 0.1 to 2 μg/μL) 
were used as a standard. Absorbance was measured at =562 nm. Typically, 5 to 10 μg of 
total protein were analyzed by immunoblot analysis. 
6.3.2 SDS-PAGE and immunoblot analysis 
For SDS-polyacrylamide gel electrophoresis (SDS-PAGE), protein samples prepared in LSB 
were separated on discontinuous polyacrylamide gels (with acrylamide concentration 
adjusted to separation range, 6 to 15 %; stacking gels 4 %). After gel electrophoresis, 
proteins were transferred onto polyvinylidenfluoride (PVDF) membranes (wet blotting; 
400 mA 1 h). The membranes were saturated in blocking buffer, thereafter the primary 
antibody was applied (diluted in blocking buffer, 4 °C, overnight). Following extensive 
washing in TBST, the secondary antibody (1:12.000 dilution in TBST) was added for 1 h at 
room temperature. Afterwards, the membranes were washed in TBST (4 times, 10 mL per 
membrane, 10 min). The luminescent signal was detected using ECL Western blotting 
detection reagents (GE Healthcare) and FUJI medical X-ray films. 
6.3.3 Detergent-solubility assay 
Cells were pelleted by centrifugation, then resuspended in lysis buffer (0.5 % (v/v) 
Triton X-100, 0.5 % (w/v) desoxycholic acid, complete protease inhibitor cocktail in PBS) and 
incubated on ice for 5 min. Following centrifugation (13.000 g, 20 min, 4 °C), supernatants 
were transferred to new vessels and supplemented with Laemmli sample buffer (LSB). The 
remaining pellet was washed with one volume of lysis buffer, centrifuged and supplemented 
with an appropriate volume of LSB. Pellet fractions were homogenized by several passages 
through a 23 gauge syringe. All samples were boiled at 95 °C for 10 min and equal volumes 
of both fractions were subjected to immunoblot analysis. 
6.4 Microscopy 
6.4.1 Indirect immunofluorescence 
Cells were grown on 15 mm glass coverslips. Prior to fixation, cells were washed with PBS 
supplemented with calcium and magnesium (PAA Laboratories). Cells were fixed in 3.7 % 
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(w/v) aqueous formaldehyde solution and permeabilized with ice-cold methanol. After 
incubation in blocking buffer (5 % (v/v) horse serum and 0.1 % Tween-20 in PBS) the 
primary antibody was added overnight (dilution dependent on antibody, range 1:200 to 
1:2.000 in PBS) at 4 °C. Following intensive washing with PBST (0.1 % Triton X-100 in PBS), 
ALEXA-conjugated secondary antibodies were added for 2 h at room temperature (1:1.000 in 
PBS). After several washes with PBST, cells were embedded in Mowiol mounting medium 
supplemented with 1 μg/mL 4',6-diamidino-2-phenylindole (DAPI) to visualize nuclei.  
6.4.2 Mitophagy assay 
For the analysis of mitophagy HeLa or MEF cells stably overexpressing wildtype human 
parkin were used. For the analysis of parkin mutant, transient liposome-mediated 
transfection was used. Cells were seeded on glass cover slips, treated with 10 μM CCCP for 
1 or 24 h and fixed in 3.7 % formaldehyde in PBS. Cells were stained using the PRK8 
anti-parkin antibodies and TOM20 or HSP60 antibodies and ALEXA-conjugated secondary 
antibodies. The percentage of cells devoid of mitochondria was counted in three independent 
experiments with at least 500 cells being analyzed for each condition.   
6.4.3 Activated caspase-3 assay 
In order to quantify apoptotic cells with activated caspase-3 a single cell assay was applied. 
For this approach, an indirect immunofluorescence was performed with an antibody 
specifically recognizing activated cleaved caspase-3. The percentage of cells positive for 
activated caspase-3 was assessed in three independent experiments with at least 300 cells 
analyzed for each condition. 
6.5 Statistical analysis 
Data were expressed as mean +/- standard deviation (SD). Statistical analysis among groups 
was carried out using the one-dimensional analysis of variance (ANOVA). P-values are 
* p<0.05, ** p<0.01, *** p<0.001. 
6.6 Software and databases 
Microsoft Office Excel 2007 was used for calculations and statistical analyses. For the 
administration of plasmids, for strategic planning of clonings and the analysis of DNA 
sequencing reactions the programs VectorNTI 10.1 and CLC Main Workbench 6.1 were 
used. Research publications were obtained from the online database NCBI PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed/) and managed with EndNote X4. DNA and protein 
sequences were obtained from NCBI (http://www.ncbi.nlm.nih.gov/nuccore and 
http://www.ncbi.nlm.nih.gov/protein) and ENSEMBL (http://www.ensembl.org). Sequence 
homology was determined via the basic local alignment search tool (BLAST). Microscopic 
pictures were processed using the Zeiss Axiovision Software 4.7 and Adobe Photoshop and 
Illustrator CS4 were used for the assembly of figures. 
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10 Summary 
 
Parkinson’s disease (PD) is the most common movement disorder and the second most 
frequent neurodegenerative disease after Alzheimer’s disease. Mutations in the parkin gene 
account for the majority of autosomal recessive PD. Parkin functions as an E3 ubiquitin 
ligase mediating the specificity of substrate ubiquitination. Various substrates have been 
proposed to be ubiquitinated by parkin, however, the in vivo relevance of them is still under 
debate. Several different functions have been attributed to parkin, the most consistently 
found being parkin-dependent mitophagy in parkin-mediated cytoprotection.  
The goal of the first part of this thesis was to gain deeper insights into the physiological 
function of parkin in mitophagy. It was shown that parkin triggers the degradation of 
dysfunctional mitochondria, but only when the membrane potential is uncoupled by 
ionophores. Other cellular stressors interfering with mitochondrial function did not induce 
parkin translocation to mitochondria and their subsequent degradation, suggesting that 
mitophagy is independent of parkin-dependent cellular stress protection. Most pathogenic 
parkin mutations impaired the removal of damaged mitochondria, and only mutations in or 
deletion of the N-terminal ubiquitin-like domain did not affect the mitophagic activity of parkin. 
In line with the notion that parkin functions as an E3 ubiquitin ligase, robust ubiquitination at 
mitochondria was observed when parkin translocated to mitochondria with disrupted 
membrane potential. It was demonstrated that parkin-mediated mitophagy crucially depends 
on both autophagy and the ubiquitin-proteasomal system. Furthermore, PINK1, a 
mitochondrial serine/threonine kinase associated with PD, is crucially involved in mitophagy. 
In fibroblasts devoid of PINK1, parkin was not targeted to dysfunctional mitochondria. Using 
an artificial chimeric protein anchoring parkin to the outer mitochondrial membrane, it was 
demonstrated that targeting of parkin to mitochondria is not sufficient to induce mitophagy. 
Interestingly, mitochondrially targeted parkin did not induce the degradation of dysfunctional 
mitochondria in the absence of PINK1, suggesting that PINK1 carries out other functions 
independent of recruitment of parkin. Indeed, PINK1 was able to alter the solubility of parkin 
in detergents, supporting the notion that structural features of parkin are crucial for its action 
in mitochondrial degradation. Notably, pathogenic mutants of PINK1 were impaired in their 
ability to render parkin insoluble. In addition, treatment with CCCP also induced a shift in 
parkin conformation to a similar extent as PINK1 expression, but this shift was abolished in 
PINK1-deficient cells. 
The second part of this thesis focused on identifying the degradation mechanisms of 
pathogenic parkin mutants. In agreement with previous results it was demonstrated that 
some pathogenic missense and truncation mutants misfold and aggregate when 
overexpressed in cells. Reminiscent of protein aggregates in various proteinopathies, the 
adapter protein p62 robustly colocalized with aggregates of mutant parkin. Cellular levels of 
p62 influenced the abundance of parkin aggregates: an increase in the percentage of cells 
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with parkin aggregates was observed in fibroblasts deficient of p62. In addition, 
overexpression of p62 was sufficient to significantly reduce the number of cells containing 
parkin aggregates. In agreement with this, mutant parkin protein accumulated upon transient 
siRNA-mediated downregulation of p62 in cell lines stably overexpressing the pathogenic 
parkin mutant W453X. Analysis of primary cortical neurons from parkin W453X mutant 
transgenic mice further revealed aggregates of parkin colocalizing with p62 and protein 
levels of the mutant parkin were increased following proteasomal inhibition. Although p62 
has been suggested to function as an adapter molecule for selective autophagy, inhibition of 
autophagy did not have an impact on the abundance of aggregates of mutant parkin. In 
contrast, inhibition of proteasomal function significantly increased the number of cells with 
parkin mutant aggregates, suggesting that pathogenic parkin mutants which are prone to 
misfolding are degraded by the proteasome in a p62-dependent manner. 
